[go: up one dir, main page]

WO2004055010A2 - Cyclopropyl compounds as ccr5 antagonists - Google Patents

Cyclopropyl compounds as ccr5 antagonists Download PDF

Info

Publication number
WO2004055010A2
WO2004055010A2 PCT/US2003/039619 US0339619W WO2004055010A2 WO 2004055010 A2 WO2004055010 A2 WO 2004055010A2 US 0339619 W US0339619 W US 0339619W WO 2004055010 A2 WO2004055010 A2 WO 2004055010A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
methyl
ring
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/039619
Other languages
French (fr)
Other versions
WO2004055010A3 (en
Inventor
Jennifer Poole Peckham
Christopher Joseph Aquino
Wieslaw Mieczyslaw Kazmierski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to DE60318891T priority Critical patent/DE60318891T2/en
Priority to AU2003296993A priority patent/AU2003296993A1/en
Priority to JP2004560831A priority patent/JP2006514950A/en
Priority to EP03813416A priority patent/EP1569934B1/en
Priority to US10/538,196 priority patent/US7569579B2/en
Publication of WO2004055010A2 publication Critical patent/WO2004055010A2/en
Publication of WO2004055010A3 publication Critical patent/WO2004055010A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • ARC AIDS-related complex
  • HIV requires a co-receptor for entry into target cells.
  • the chemokine receptors function together with CD4 as co-receptors for HIV.
  • the chemokine receptors CXCR4 and CCR5 have been identified as the main co- receptors for HIV-1.
  • CCR5 acts as a major co-receptor for fusion and entry of macrophage-tropic HIV into host cells. These chemokine receptors are thought to play an essential role in the establishment and dissemination of an HIV infection. Therefore, CCR5 antagonists are thought to be useful as therapeutic agents active against HIV.
  • the present invention features compounds that are useful in the inhibition of HIV replication, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS and/or ARC, either as pharmaceutically acceptable salts or pharmaceutical composition ingredients.
  • the present invention further features methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV as monotherapy or in combination with other antivirals, anti- infectives, immunomodulators, antibiotics or vaccines.
  • the present invention also features pharmaceutical compositions, comprising the above-mentioned compounds that are suitable for the prevention or treatment of CCR5-related diseases and conditions.
  • the present invention further features processes for making the above- mentioned compounds.
  • Ring A is a saturated, partially saturated or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
  • R 1 is selected from the group consisting of (a) a saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, optionally attached through a
  • Ci-e alkylene chain and optionally substituted by one or more R 8 ;
  • Q is carbon, oxygen, or S(O) t ; w is 1 or 2; each R 2 is independently selected from the group consisting of -OR 0 ,
  • R + is alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, or heterocyclyl, wherein said R + is optionally substituted by one or more R 8 ; d is 0-3; m is 0 or 1; n is 0-5;
  • R 3 is H, -N(R°) 2 , -N(R°)C(O)R°, -CN, halogen, CF 3 , alkyl optionally substituted by one or more groups selected from R 7 or -S-aryl optionally substituted by -(CH 2 ) ⁇ -6-N(R 0 )SO 2 (R 0 ), alkenyl optionally substituted by one or more groups selected from R 7 or -S-aryl optionally substituted by -(CH 2 ) ⁇ -6-N(R 0 )S ⁇ 2 (R°), alkynyl optionally substituted by one or more groups selected from R 7 or -S-aryl optionally substituted by -(CH 2 ) ⁇ -6-N(R)SO 2 (R 0 ), cycloalkyl or carbocyclyl optionally substituted by one or more R 8 , aryl optionally substituted by one or more R 6 , heteroaryl optionally substituted by one or more R 6 ,
  • R 10 is optionally substituted aryl, such as optionally substituted phenyl.
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 9 is alkyl and preferably R 9 is methyl.
  • -(Y) m -R 3 suitably is
  • R 1 is selected from
  • X is -(CH 2 )-, -(CH 2 -CH 2 )-, or -(CH 2 -CH 2 -CH 2 )-.
  • X is optionally substituted by one or more halogen or oxo.
  • X optionally has 1-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen.
  • the A ring is selected from the following, where the asterisk (*) indicates the preferred, but not limiting, point(s) of substitution:
  • each R 2 with the asterisk (*) indicating a preferred, but not limiting, point of substitution from Ring A, independently is selected from
  • the ring A with two geminal R 2 s, is selected from:
  • a ring is tropane or piperidine, either optionally substituted with one or more R 2 .
  • A--R 2 is comprised of one of the following:
  • the A ring contains at least one additional nitrogen atom and said A ring optionally is N-substituted.
  • the A ring is N-substituted with -(CH 2 ) a -(V b -R+).
  • Another aspect of the present invention includes a method of treatment including prevention of a viral infection in a mammal comprising administering to said mammal an antiviral effective amount of a compound of the present invention.
  • the viral infection is an HIV infection.
  • Another aspect of the present invention includes a method of treatment including prevention of a bacterial infection in a mammal comprising administering to said mammal an effective amount of a compound of the present invention.
  • the bacterium is Yersinia pestis.
  • Another aspect of the present invention includes a method of treatment including prevention of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders in a mammal comprising administering to said mammal a pharmaceutically effective amount of a compound of the present invention.
  • Another aspect of the present invention includes a compound of the present invention for use in medical therapy.
  • Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a viral infection.
  • the viral infection is a HIV infection.
  • Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a bacterial infection.
  • the bacterium is Yersinia pestis.
  • Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders.
  • Another aspect of the present invention includes a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the present invention together with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is in the form of a tablet, a capsule, or a liquid.
  • compositions comprising a compound of the present invention and another therapeutic agent.
  • the composition comprises one or more therapeutic agent selected from the group consisting of (1 -alpha, 2-beta, 3-alpha)-9-[2,3- bis(hydroxymethyl) cyclobutyljguanine [(-)BHCG, SQ-34514, lobucavir], 9- [(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir, acyclic nucleoside phosphonates, (S)-1 -(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPM
  • Another aspect of the present invention includes a method of treatment or prevention of a viral infection in a mammal comprising administering to said mammal a composition comprising a compound of the present invention and ritonavir.
  • Particular compounds of the present invention include:
  • an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
  • alkyl alone or in combination with any other term, refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
  • cycloalkyl refers to a monocyclic or polycyclic non-aromatic hydrocarbon ring radical having three to twenty carbon atoms, preferably from three to twelve carbon atoms, and more preferably from three to ten carbon atoms. If polycyclic, each ring in a carbocylyl radical is non-aromatic unless otherwise indicated.
  • a carbocylyl radical is either completely saturated or contains one or more units of unsaturation but is not aromatic. The unsaturation, if present, may occur in any point in the ring that may result in any chemically stable configuration.
  • cycloalkyl also includes hydrocarbon rings that are fused to one or more aromatic rings, such as in tetrahydronaphthyl, where the radical or point of attachment is on the non-aromatic ring.
  • cycloalkyl also includes each possible positional isomer of a non-aromatic hydrocarbon radical, such as in 1-decahydronaphthyl, 2- decahydronaphthyl, 1 -tetrahydronaphthyl and 2-tetrahydronaphthyl.
  • Suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, decahydronaphthyl, tetrahydronaphthyl and the like.
  • alkenyl refers to a straight-chain or branched-chain alkyl group with at least one carbon-carbon double bond.
  • alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, hexadienyl and the like.
  • alkynyl refers to hydrocarbon groups of either a straight or branched configuration with one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, butynyl, pentynyl, and the like.
  • alkoxy refers to an alkyl ether radical, wherein the term “alkyl” is defined above.
  • suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert- butoxy and the like.
  • aryl refers to an aromatic monocyclic or polycyclic hydrocarbon ring radical containing five to twenty carbon atoms, preferably from six to fourteen carbon atoms, and more preferably from six to ten carbon atoms. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aromatic hydrocarbon ring is fused to one or more non-aromatic carbocyclic or heteroatom-containing rings, such as in an indanyl, phenanthridinyl or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic hydrocarbon ring.
  • aryl also includes each possible positional isomer of an aromatic hydrocarbon radical, such as in 1-naphthyl, 2- naphthyl, 5-tetrahydronaphthyl, 6-tetrahydronaphthyl, 1 -phenanthridinyl, 2- phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 7-phenanthridinyl, 8- phenanthridinyl, 9-phenanthridinyl and 10-phenanthridinyl.
  • aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like.
  • aralkyl further refers to groups of -R a R b , where R a is an alkylene as defined herein and R b is an aryl as defined herein.
  • heterocycle refers to a non-aromatic monocyclic or polycyclic ring radical containing three to twenty carbon atoms, preferably three to seven carbon atoms if monocyclic and eight to eleven carbon atoms if bicyclic, and in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, and S. If polycyclic, each ring in a heterocyclyl radical is non-aromatic unless otherwise indicated.
  • a heterocyclic ring may be fully saturated or may contain one or more units of unsaturation but is not aromatic.
  • the unsaturation may occur in any point in the ring that may result in any chemically stable configuration.
  • the heterocyclic ring may be attached at a carbon or heteroatom that results in the creation of a stable structure.
  • Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles.
  • heterocycle is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring.
  • heterocycle also includes each possible positional isomer of a heterocyclic radical, such as in 1-decahydroquinoline, 2-decahydroquinoline, 3- decahydroquinoline, 4-decahydroquinoline, 5-decahydroquinoline, 6- decahydroquinoline, 7-decahydroquinoline, 7-decahydroquinoline, 8- decahydroquinoline, 4a-decahydroquinoline, 8a-decahydroquinoline, 1 -indolinyl, 2- indolinyl, 3-indolinyl, 1-tetrahydroquinoline, 2-tetrahydroquinoline, 3- tetrahydroquinoline and 4-tetrahydroquinoline.
  • heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl.
  • heterocyclic groups include, but are not limited to, imidazolinyl, 2,3-dihydro-1 H-imidazolyl, imidazolidinyl, indazolinolyl, perhydropyridazyl, pyrrolinyl, pyrrolidinyl, 4H-pyrazoIyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, morpholinyl, thiamorpholinyl, thiazolidinyl, thiamorpholinyl, oxopiperidinyl, oxopyrrolidinyl, azepinyl, tetrahydrofuranyl, oxoazepinyl, tetrahydropyranyl, thiazolyl, dioxolyl, dioxinyl, oxathiolyl, benzodioxolyl, dithiolyl, dithiolanyl, te
  • heteroaryl refers to an aromatic monocyclic or polycyclic ring radical containing five to twenty carbon atoms, preferably five to ten carbon atoms, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, and S.
  • Preferred heteroaryl groups include 5-6 membered monocyclic heteroaryls and 8-10 membered bicyclic heteroaryls.
  • heteroaryl is a group in which a heteroaromatic ring is fused to one or more aromatic or non-aromatic rings where the radical or point of attachment is on the heteroaromatic ring.
  • heteroaromatic rings include, but are not limited to, pyrido[3,4-d]pyrimidinyl, 7,8-dihydro-pyrido[3,4-d]pyrimidine and 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidine.
  • heteroaryl also includes each possible positional isomer of a heteroaryl radical, such as in 2-pyrido[3,4-d]pyrimidinyl and 4-pyrido[3,4-d]pyrimidinyl.
  • heteroaryl groups include, but are not limited to, imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl, pyridyl, pyrrolyl, pyrazolyl, pyrazinyl, quinoxalyl, pyrimidinyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, carbazolyl, carbolinyl, tetrazolyl, benzofuranyl, oxazolyl, benzoxazolyl, isoxozolyl, isothiazolyl, thiadiazolyl, furazanyl, oxadiazolyl, benzimidazolyl, benzothienyl, quinolinyl, benzotriazolyl, benzothiazolyl, isoquinolinyl, isoindolyl, acridinyl and benzoisox
  • heteroaryl further refers to groups of -R a R b , where R a is an alkylene as defined herein and R is a heteroaryl as defined herein.
  • heteroatom means nitrogen, oxygen, phosphorus, or sulfur and includes any oxidized forms thereof, including as non-limiting examples oxidized forms of nitrogen such as N(O) ⁇ N + -O " ⁇ , oxidized forms of sulfur such as S(O) and S(O) 2 , and the quatemized form of any basic nitrogen.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • pharmaceutically effective amount refers to an amount of a compound of the invention that is effective in treating a CCR5-related disease, for example a virus infection, for example an HIV infection, in a patient either as monotherapy or in combination with other agents.
  • treatment refers to the alleviation of symptoms of a particular disorder in a patient, or the improvement of an ascertainable measurement associated with a particular disorder, and may include the suppression of symptom recurrence in an asymptomatic patient such as a patient in whom a viral infection has become latent.
  • prophylaxis refers to preventing a disease or condition or preventing the occurrence of symptoms of such a disease or condition, in a patient.
  • patient refers to a mammal, including a human.
  • pharmaceutically acceptable carrier refers to a carrier that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the therapeutic agent.
  • pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • Pharmaceutically acceptable salts of the compounds according to the invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicyclic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
  • Other acids, such as oxalic while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium, NW 4 + (wherein W is C 1-4 alkyl) and other amine salts.
  • Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
  • Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as Na + , NH + , and NW 4 + (wherein W is a C 1-4 alky
  • Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof.
  • Salts of the compounds of the present invention may be made by methods known to a person skilled in the art. For example, treatment of a compound of the present invention with an appropriate base or acid in an appropriate solvent will yield the corresponding salt.
  • Esters of the compounds of the present invention are independently selected from the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted by, for example, halogen, C ⁇ alkyl, or C- ⁇ alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl);
  • any alkyl moiety present in such esters advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms, Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.
  • the compounds according to the invention contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereoisomers. All such isomeric forms of these compounds are expressly included in the present invention.
  • Each stereogenic carbon may be of the R or S configuration.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are also within the scope of this invention.
  • the present invention features compounds according to the invention for use in medical therapy, for example for the treatment including prophylaxis of viral infections such as an HIV infections and associated conditions.
  • Reference herein to treatment extends to prophylaxis as well as the treatment of established infections, symptoms, and associated clinical conditions such as AIDS related complex (ARC), Kaposi's sarcoma, and AIDS dementia.
  • ARC AIDS related complex
  • Kaposi's sarcoma Kaposi's sarcoma
  • AIDS dementia AIDS related complex
  • the present invention features use of the compounds of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a CCR5-related disease or condition, for example, a viral infection, for example, an HIV infection.
  • a CCR5-related disease or condition for example, a viral infection, for example, an HIV infection.
  • the present invention provides a method for the treatment including prevention of the symptoms or effects of a viral infection in an infected animal, for example, a mammal including a human, which comprises treating said animal with a pharmaceutically effective amount of a compound according to the invention.
  • the viral infection is a retroviral infection, in particular an HIV infection.
  • a further aspect of the invention includes a method for the treatment including prevention of the symptoms or effects of an HBV infection.
  • the compounds according to the invention may also be used in adjuvant therapy in the treatment of HIV infections or HIV-associated symptoms or effects, for example Kaposi's sarcoma.
  • the compounds of the present invention may also be used in the treatment including prevention of other CCR5-related diseases and conditions, including multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis, immune mediated disorders.
  • CCR5-related diseases and conditions including multiple sclerosis, rheumatoid arthritis,
  • the present invention further provides a method for the treatment of a clinical condition in an animal, for example, a mammal including a human which clinical condition includes those which have been discussed hereinbefore, which comprises treating said animal with a pharmaceutically effective amount of a compound according to the invention.
  • the present invention also includes a method for the treatment including prophylaxis of any of the aforementioned diseases or conditions.
  • the present invention provides the use of a compound according to the invention in the manufacture of a medicament for the treatment including prophylaxis of any of the above mentioned viral infections or conditions.
  • Combination therapies according to the present invention comprise the administration of a compound of the present invention or a pharmaceutically acceptable derivative thereof and another pharmaceutically active agent.
  • the active ingredient(s) and pharmaceutically active agents may be administered simultaneously in either the same or different pharmaceutical compositions or sequentially in any order.
  • the amounts of the active ingredient(s) and pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • agents that are effective for the treatment of viral infections or associated conditions include agents that are effective for the treatment of viral infections or associated conditions.
  • these agents are (1- alpha, 2-beta, 3-alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ- 34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, for example acyclovir, valaciclovir, famciclovir, ganciclovir, and penciclovir, acyclic nucleoside phosphonates, for example (S)-1-(3- hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9- yl)ethoxy]methyl]phos
  • Compounds of the present invention may be administered with an agent known to inhibit or reduce the metabolism of compounds, for example ritonavir. Accordingly, the present invention features a method for the treatment including prophylaxis of a disease as hereinbefore described by administration of a compound of the present invention in combination with a metabolic inhibitor. Such combination may be administered simultaneously or sequentially.
  • a suitable dose for each of the above-mentioned conditions will be in the range of 0.01 to 250 mg per kilogram body weight of the recipient (e.g. a human) per day, preferably in the range of 0.1 to 100 mg per kilogram body weight per day and most preferably in the range 0.5 to 30 mg per kilogram body weight per day and particularly in the range 1.0 to 20 mg per kilogram body weight per day.
  • all weights of active ingredient are calculated as the parent compound of formula (I); for salts or esters thereof, the weights would be increased proportionally.
  • the desired dose may be presented as one, two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In some cases the desired dose may be given on alternative days. These sub- doses may be administered in unit dosage forms, for example, containing 10 to 1000 mg or 50 to 500 mg, preferably 20 to 500 mg, and most preferably 50 to 400 mg of active ingredient per unit dosage form.
  • compositions of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents.
  • Each carrier must be acceptable in the sense of being compatible with the other ingredients of the composition and not injurious to the patient.
  • Phamaceutical compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and intravitreal) administration.
  • the compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier, which constitutes one or more accessory ingredients.
  • the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • the present invention further includes a pharmaceutical composition as hereinbefore defined wherein a compound of the present invention or a pharmaceutically acceptable derivative thereof and another therapeutic agent are presented separately from one another as a kit of parts.
  • compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer.
  • a suitable concentration of the active compound is about 1% to 25%, preferably about 3% to 15%.
  • the active compound may be delivered from the patch by electrotransport or iontophoresis as generally described in Pharmaceutical Research 3 (6), 318 (1986).
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent.
  • Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray Pharmaceutical compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • compositions for rectal administration may be presented as a suppository with a suitable carrier comprising, for example, cocoa butter or a salicylate or other materials commonly used in the art.
  • a suitable carrier comprising, for example, cocoa butter or a salicylate or other materials commonly used in the art.
  • the suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • compositions suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti- oxidants, buffers, bacteriostats and solutes which render the pharmaceutical composition isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
  • compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Unit dosage pharmaceutical compositions include those containing a daily dose or daily subdose of the active ingredients, as hereinbefore recited, or an appropriate fraction thereof.
  • compositions of this invention may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
  • R2-X an alkyl halide
  • Phenylacetonitrile (4.59g, 39.2mmol) and (2S)-2-hydroxy-3-[(phenylmethyl)oxy]propyI 4-methylbenzenesulfonate (13.20g, 39.2mmol, 1eq) were dissolved in 50mL THF, cooled to -78°C, and treated with 2.5M butyllithium in hexanes (35mL, 86.3mmol, 2.2eq) added dropwise over 30min. The reaction mixture was stirred 4h at -78°C, allowed to warm to ambient temperature and stirred an additional 16h.
  • the reaction mixture was stirred at 0°C for 16h, then washed successively with water and brine, dried over MgSO 4 , filtered and concentrated to give a yellow oil that was shown to be an 8:2 diastereomeric mixture of the title compound to the product of Preparation 3A.
  • the desired diastereomer (16.0 g, 62%) was separated by silica gel flash chromatography using 9:1 ⁇ 8:2 hexanes in ethyl acetate.
  • lodomethane (2.12g, 14.9mmol, 4eq) was added portionwise to ⁇ /-[((1S,2R)-1- phenyl-2- ⁇ [(phenylmethyl)oxy]methyl ⁇ cycIopropyl)methyl]benzenesulfonamide (1.71 g, 3.74mmol, 1eq), accessed via the method of preparation 5A, in 7mL DMF with potassium carbonate (1.03g, 7.48mmol, 2eq) over 6h at 80°C. Following addition, the reaction mixture was stirred 16h at 80°C.
  • the reaction mixture was diluted with EtOAc, washed successively with saturated aqueous NaHCO 3 , water (4x) and brine, dried over MgSO 4 , filtered and concentrated to give a brown oil.
  • the crude material was purified by flash chromatography (SiO 2 , eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (1.57g, 100%) as a yellow oil.
  • Preparation 6B ⁇ /-methyl- ⁇ /-[((1R,2R)-1-phenyl-2- ⁇ [(phenylmethyl)oxy]methyl ⁇ cyclopropyl)methyl]benzenesulfonamide lodomethane (2.12g, 14.9mmol, 4eq) was added portionwise to ⁇ /-[((1R,2R)-1- phenyl-2- ⁇ [(phenylmethyl)oxy]methyl ⁇ cyclopropyl)methyl]benzenesulfonamide (1.71g, 3.74mmol, 1eq), accessed via the method of preparation 5B, in 7mL DMF with potassium carbonate (1.03g, 7.48mmol, 2eq) over 6h at 80°C.
  • reaction mixture was stirred 16h at 80°C.
  • the reaction mixture was diluted with EtOAc, washed successively with saturated aqueous NaHCO 3 , water (4x) and brine, dried over MgSO 4 , filtered and concentrated to give a brown oil.
  • the crude material was purified by flash chromatography (SiO 2 , eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (1.57g, 100%) as a yellow oil.
  • the organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO 4 , filtered and concentrated to a colorless oil.
  • the crude material was purified by flash chromatography (SiO 2 , eluted successively with DCM, EtOAc/hexanes (1 :4)) to the title product (270mg, 0.82mmol, 45%) as a colorless oil.
  • the organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO 4 , filtered and concentrated to a colorless oil.
  • the crude material was purified by flash chromatography (SiO 2 , eluted successively with DCM, EtOAc/hexanes (1 :4)) to the title product (410mg, 1.24mmol, 69%) as a colorless oil.
  • Example 1 ⁇ /-[((1S,2R)-2- ⁇ [4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidin-1-yl]methyl ⁇ -1- phenylcyclopropyl)methyl]- ⁇ /-methylbenzenesulfonamide
  • Example 5 ⁇ /-[((1 S,2R)-1-(3-chlorophenyl)-2- ⁇ [(3-exo)-3-(2-methyl-1H-benzimidazol- 1 -yl)-8-azabicyclo[3.2.1 ]oct-8-yl]methyl ⁇ cyclopropyl)methylj-/V- methylbenzenesulfonamide
  • Example 6 ⁇ /- ⁇ [(1 S,2R)-2- ⁇ [4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidin-1 -yl]methyl ⁇ -1 - (3-chIorophenyl)cyclopropyl]methyl ⁇ - ⁇ /-methylbenzenesulfonamide
  • the compounds prepared according to the method of Preparation 16 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • the reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF.
  • the resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h.
  • the reaction plates were filtered and the filtrates concentrated to dryness.
  • Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer.
  • Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes.
  • a Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
  • the compounds prepared according to the method of Preparation 16 were dissolved in 3mL DCE (1:1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE.
  • the resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h.
  • reaction plates were filtered and the filtrates concentrated to dryness.
  • Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol.
  • This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm).
  • Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes.
  • a Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
  • the reaction mixture was diluted with DCM, washed successively with saturated NaHCO 3 and brine, dried over MgSO 4 , filtered and concentrated down.
  • the crude material was purified by flash chromatography (SiO 2 , eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (5.9 g, 15.46 mmol, 85%) as a clear oil.
  • aldehydes prepared by the methods of Preparations 27A-F (0.35mmol) in 3mL DCE were treated with various secondary amines (0.35mmol, 1eq) and mp-sodium triacetoxyborohydride (500mg, 1.04mmol, 3eq) at ambient temperature for 20h with continuous agitation.
  • the reaction mixtures were each filtered.
  • the remaining resin was treated with 4mL DCM with agitation for 1h and the organics separated via filtration.
  • the organic filtrates were concentrated to dryness and carried forward without purification or characterization.
  • the compounds prepared according to the method of Preparation 29 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • the reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF.
  • the resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h.
  • the reaction plates were filtered and the filtrates concentrated to dryness.
  • Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C185 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer.
  • the compounds prepared according to the method of Preparation 29 were dissolved in 3mL DCE (1:1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE.
  • the resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h.
  • aldehydes prepared by the method of Preparations 37A-B (0.35mmol) in 3mL DCE were treated with various secondary amines (0.35mmol, 1eq) and mp-sodium triacetoxyborohydride (500mg, 1.04mmol, 3eq) at ambient temperature for 20h with continuous agitation.
  • the reaction mixtures were each filtered.
  • the remaining resin was treated with 4mL DCM with agitation for 1h and the organics separated via filtration.
  • the organic filtrates were concentrated to dryness and carried forward without purification or characterization.
  • the compounds prepared according to the method of Preparation 39 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • the reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF.
  • the resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h.
  • the reaction plates were filtered and the filtrates concentrated to dryness.
  • Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer.
  • the compounds prepared according to the method of Preparation 39 were dissolved in 3mL DCE (1 :1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE.
  • Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE.
  • the resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h.
  • HPLC HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
  • Example 12 ⁇ /-[((1 S,2S)-1 -(3-chlorophenyl)-2- ⁇ 2-[1 -(3-methylphenyl)-4-oxo-1 ,3,8- triazaspiro[4.5]dec-8-yl]ethyl ⁇ cyclopropyl)methyl]- ⁇ /-methylcyclopentanecarboxamide
  • the organic phase was combined with fresh water and the pH adjusted to 2 with 1 N HCI.
  • the aqueous phase was isolated, the pH adjusted to 11 with 1 N NaOH, and extracted with DCM.
  • the organic phase was isolated, dried over MgSO4, filtered and concentrated to give the title compound (574mg, 1.29mmol, 68%) as a brown foam.
  • Ethyl (1 S,2R)-2- ⁇ [(3-er?ofo)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8-azabicyclo[3.2.1 joct- 8-yl]methyl ⁇ -1-phenylcyclopropanecarboxylate (574mg, 1.29mmol, 1eq.) was dissolved in 1.9mL ethyl alcohol and treated with 1.9mL 1 N LiOH (1.9mmol, 1.5eq.) 16h at ambient temperature. The reaction mixture was concentrated to dryness, chased three times with toluene and pumped on under high vacuum to dryness.
  • the acid chloride thus obtained was suspended in 5mL acetone and treated with sodium azide (73mg, 1.12mmol, 2.7eq.) dissolved in 2mL water at ambient temperature.
  • the reaction mixture was stirred 1 h at ambient temperature and then diluted with saturated NaHCO 3 and extracted with toluene.
  • the toluene layer was isolated, dried over MgSO 4 , filtered, and the filtrate heated at 90°C for 2h. After cooling, water was added to the reaction mixture and the pH adjusted to 2 with 1 N HCI.
  • Example 14 ⁇ /-((1R,2R)-2- ⁇ [(3-e/7Qfo)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8- azabicyclo[3.2.1 ]oct-8-yl]methyl ⁇ -1 -phenylcyclopropyl)benzenesulfonamide
  • LAH lithium aluminum hydride
  • DCE dichloroethane
  • LHMDS lithium bis(trimethylsilyl)amide
  • NaHMDS sodium bis(trimethylsily!amide
  • PS-DIEA polystyrene supported diisopropylethylamine
  • PS-Trisamine polystyrene supported trisamine
  • HATU O-(7-azabenzotriazol-1-yl)- ⁇ /, ⁇ , ⁇ /', ⁇ /-tetramethyluronium hexafluorophosphate
  • DMF ⁇ /,/V-Dimethylformamide
  • DMSO Dimethyl sulfoxide
  • DIEA ⁇ /, ⁇ /-Diisopropylethylamine
  • THF Tetrahydrofuran
  • NaBH(OAc) 3 sodium triacetoxyborohydride
  • EtOAc ethyl acetate
  • BIOLOGICAL DATA The following definitions apply:
  • IC 50 Concentration of compound that displaces 50% of radioligand plC 50 The determined IC 50 value expressed as -log10(IC 50 )
  • CCR5 SPA Scintillation Proximity Assay for the Human CC-Chemokine Receptor
  • This protocol describes a high-throughput screen using SPA binding to identify compounds that inhibit binding of 125 l-MIP1 ⁇ to the human CCR5 chemokine receptor.
  • CCR5 is a G protein-coupled receptor that binds the natural chemokine ligands
  • CCR5 acts as a co-receptor with CD4 for entry of HIV- 1 into human T-cells and monocytes.
  • Chemokines also play a role in acute and chronic inflammatory processes. Chemokines are soluble proteins produced and released by a wide variety of cell types during the initial phase of a host response to a forgein substance entering the body.
  • Human CCR5 receptors were expressed in Chinese Hamster Ovary (CHO) cells, registration # 12025. Cells were grown in suspension and a 50 to 80 ml CCR5 cell pellet was prepared.
  • Membrane preparation 1) Weigh pellet; 2)Prepare an ice-cold 50mM HEPES buffer, containing 0.0025mg/ml Pefabloc, 0.0001 mg/ml Pepstatin A, 0.0001 mg/ml Leupeptin, 0.0001 mg/ml Aprotinin (protease inhibitor cocktail), pH 7.4; 3) Homogenize pellet in 5 volumes of HEPES buffer; 4) Homogenize again with a glass homogenizer 10 to 20 strokes; 5) Centrifuge homogenate at 18,000 rpm in a F28/36 rotor using a Sorvall RC26 PIUS refrigerated Centrifuge for 30 minutes; 6) Discard supernatant and resuspend pellet in 3 volumes of HEPES buffer; 7) Homogenize and centr
  • the saturation curve binding experiment is performed by adding varying amounts of [ 125 l]MIP1 ⁇ (0-8.5nM to membranes and beads in concentrations chosen from the optimal protein/bead ratio.
  • the data is analyzed using a non-linear curve-fitting program.
  • the K d and Bmax are derived from the curve.
  • Bacitracin 50mg/ml is dissolved in deionized water, brought to a boil for 5 minutes (to destroy protease activity) and cooled. Prepared 1ml aliquots and store at -80°C.
  • Protease inhibitor cocktail is prepared by dissolving 25 mg/ml of Pefabloc, 1 mg/ml of Leupeptin, 1 mg/ml of Aprotinin and 1 mg/ml of Pepstatin A in 100% DMSO. The cocktail can be aliquoted and stored frozen at -20°C until needed.
  • Sigmacote Any reagent bottles and reservoirs that come in contact with the radioligand are treated with Sigmacote to reduce sticking. Rinse containers with undiluted Sigmacote; rinse with deionized water several times, and allow to air dry before using.
  • Compounds Preparation Compounds for a single concentration determination (One Shots) are delivered in 96 well Packard Optiplates containing 1 ⁇ l of compound in 100% DMSO in columns A1- H10 (80 compounds/plate). Column A11 to H11 is used for total binding (Bo) (vehicle-5 ⁇ l of the appropriate DMSO concentration) and column A12 to D12 is used for determination of nonspecific binding. No further preparation is required.
  • the final assay concentration for the membrane is 15 ⁇ g per well.
  • SPA beads are prepared by adding 5 ml of assay buffer to a 500 mg vial. The final concentration of SPA beads in the assay is 0.25 mg/well.
  • Membranes and beads are premixed as a 1 :1 (membrane: bead) mixture and maintained at mixture at 4°C with constant stirring. 50 ⁇ l of the mixture is added to each assay well. After all reagents have been added to the plates (total assay volume 100 ⁇ l), shake plates for 4 hours at room temperature. After 4 hours, place the plates on the TopCount in a count the plates on the TopCount for 30 sec per well using an appropriate program (i.e., one with a quench curve established for the conditions of the assay.
  • the result of each test well is expressed as % inhibition using the following formula: 100*(1-(U1-C2)/(C1-C2)).
  • U1 is the unknown sample in cpm observed in a particular well
  • C1 is the average of column 12 cpm observed in the absence of any added inhibitor
  • C2 is the average of column 11 cpm observed in the presence of 1 ⁇ M of MIP1 ⁇ .
  • %B/Bo % total specific binding
  • Each plate contains 12 wells of total binding (column A11-H11). The cpm/well are averaged and are used in data reduction as value d .Each plate also contains 4 wells of non-specific binding (wells A12-D12). The counts of these wells are averaged and used in data reduction as value C2.
  • a standards plate is included in each experiment. This plate contains a 14-point concentration-response curve (in triplicate) for the standard compound MIP1 ⁇ at a starting concentration of 1 ⁇ M. The average historical pKj obtained with MIP1 ⁇ is 7.6.
  • HOS Assay Also referred to as HOS-LTR-Luciferase Assay
  • Trpsin-EDTA (GibcoBRL #25300-054)
  • FBS Fetal Bovine Serum
  • PBS Phosphate Buffered Saline
  • DMSO Dimethyl Sulfoxide
  • the cells were propagated in DMEM containing 2% FBS. Cells were split by standard trypsinization when confluency reached 80% (roughly every 2 to 3 days).
  • HIV-1 virus stocks were titered in the assay system in order to obtain an estimate of the number of infectious particles per unit volume (described as RLU/ml). Virus stocks were diluted into DMEM containing 2% FBS and assayed as described in the "procedure" section below.
  • Black-walled 96-well tissue culture plates were seeded with HOS-CD4.CCR5-LTR- Luciferase @ 0.6 to 1.2 x 10 3 cells per well in 50ul DMEM containing 2% FBS and placed in a humidified incubator @ 37°C, 5% CO 2 overnight. The following day, test compounds were titrated 4-fold at 2X the final concentration in DMEM + 2% FBS + 0.2% DMSO. 50 ⁇ l of titrated compound was transferred to the HOS cells and the plates were placed in a humidified incubator at 37°C, 5% CO 2 for 1hr.
  • RLU Relative Light Units
  • % control RLU at drug [ ] / RLU no drug
  • K is IC 50
  • Y2 is baseline
  • N is Hill Coefficient
  • Each of the compounds of the present invention provides a plC 50 value of at least 5 when tested in each of the above-described assays.
  • Test compounds are employed in free or salt form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)

Abstract

The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

Description

CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
BACKGROUND OF THE INVENTION
The human immunodeficiency virus ("HIV") is the causative agent for acquired immunodeficiency syndrome ("AIDS"), a disease characterized by the destruction of the immune system, particularly of CD4+ T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex ("ARC"), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss.
In addition to CD4, HIV requires a co-receptor for entry into target cells. The chemokine receptors function together with CD4 as co-receptors for HIV. The chemokine receptors CXCR4 and CCR5 have been identified as the main co- receptors for HIV-1. CCR5 acts as a major co-receptor for fusion and entry of macrophage-tropic HIV into host cells. These chemokine receptors are thought to play an essential role in the establishment and dissemination of an HIV infection. Therefore, CCR5 antagonists are thought to be useful as therapeutic agents active against HIV.
We have now discovered a series of small molecule nonpeptide compounds that are useful as inhibitors of HIV replication.
BRIEF DESCRIPTION OF THE INVENTION
The present invention features compounds that are useful in the inhibition of HIV replication, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS and/or ARC, either as pharmaceutically acceptable salts or pharmaceutical composition ingredients. The present invention further features methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV as monotherapy or in combination with other antivirals, anti- infectives, immunomodulators, antibiotics or vaccines. The present invention also features pharmaceutical compositions, comprising the above-mentioned compounds that are suitable for the prevention or treatment of CCR5-related diseases and conditions. The present invention further features processes for making the above- mentioned compounds.
SUMMARY OF THE PRESENT INVENTION The present invention includes compounds of formula (I):
Figure imgf000003_0001
or pharmaceutically acceptable derivatives thereof, wherein:
X is a C-ι-5 alkylene chain, wherein said X is optionally substituted by one or more =O, =S, alkyl, or halogen and wherein said C-ι-5 alkylene chain may optionally have 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
Ring A is a saturated, partially saturated or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
R1 is selected from the group consisting of (a) a saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, optionally attached through a
Ci-e alkylene chain, and optionally substituted by one or more R8;
(b)
(c)
( )
Figure imgf000003_0002
Figure imgf000004_0001
Q is carbon, oxygen, or S(O)t; w is 1 or 2; each R2 is independently selected from the group consisting of -OR0,
-C(O)-R°, -S(O)2-R°, -C(O)-N(R°)2, -S(O)2-N(R°)2, -(CH2)a-N(R°)(-Vb-R+), -(CH2)a-(-Vb-R+), halogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by one or more R6, cycloalkyl optionally substituted by one or more R8, and heterocyclyl optionally substituted by one or more R8; and two adjacent R2s on Ring A are optionally taken together to form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen; or two geminal R2s are optionally taken together to form a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, said fused or spiro ring being optionally substituted by one or more R8; each a independently is 0-3; each b independently is 0 or 1 ; V is -C(O)-, -C(O)O-, -S(O)2-, or -C(O)-N(R°)-;
R+ is alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, or heterocyclyl, wherein said R+ is optionally substituted by one or more R8; d is 0-3; m is 0 or 1; n is 0-5;
R3 is H, -N(R°)2, -N(R°)C(O)R°, -CN, halogen, CF3, alkyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)ι-6-N(R0)SO2(R0), alkenyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)ι-6-N(R0)Sθ2(R°), alkynyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)ι-6-N(R)SO2(R0), cycloalkyl or carbocyclyl optionally substituted by one or more R8, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by one or more R6, or heterocyclyl optionally substituted by one or more R8;
Y is alkyl, alkenyl, alkynyl, -(CR4R5)P-, -C(O)-, -C(O)C(O)-, -C(S)-, -0-(C 2 -C(0)-, -(CH2)o- -C(O)-O-, -N(R°)-C(O)-, -C(O)-N(R0)-, -N(R°)-C(S)-, -S(O)Γ, -O-C(=N-CN)-, -O-C(=N-R0)-, -C(=N-CN)-O-, -C(=N-CN)-S-, -C(=N-R°)-O-, -S-C(=N-CN)-, -N(R°)-C(=N-CN)-, -C(=N-CN)-, -N(R°)-C[=N-C(O)-R°], -N(R°)-C[=N-S(O)t-R°], -N(R°)-C(=N-OR0)-, -N(R°)-C(=N-R0)-, or -C(=N-R0)-; each R4 is independently H or alkyl optionally substituted by R7, alkenyl optionally substituted by R7, or alkynyl optionally substituted by R7; each R5 is independently selected from the group consisting of H, -C(O)-OR6, -C(O)-N(R°)2, -S(O)ΓN(R°)2, -S(O)t-R°, aryl optionally substituted by R6, and heteroaryl optionally substituted by R6; p is 1-5; each t independently is 1 or 2; each R6 is independently selected from the group consisting of halogen, -CF3) -OCF3, -OR0, -(CH2)ι-6-OR°, -SR°, -(CH2)ι-6-SR0, -SCF3, -R°, methylenedioxy, ethylenedioxy, -NO2, -CN, -(CH2)ι.e-CN, -N(R°)2, -(CH2)1-6-N(R0)2, -NR°C(O)R°, -NR°(CN), -NR0C(O)N(R°)2, -NR°C(S)N(R°)2, -NR°CO2R0, -NR0NR°C(O)R0, -NR°NR0C(O)N(R0)2, -NR0NR°CO2R0, -C(O)C(O)R°, -C(O)CH2C(O)R°,
-(CHs eCOsR0, -O-C(O)R°, -C(O)R°, -C(O)N(R°)N(R°)2l -C(O)N(R°)2, -C(O)N(R°)OH, -C(O)N(R°)SO2R°, -OC(O)N(R°)2, -S(O)tR°, -S(O)rOR°, -S(O)tN(R°)C(O)R°, -S(O)tN(R0)OR0, -NR°SO2N(R°)2, -NR°SO2R°, -C(=S)N(R°)2, -C(=NH)-N(R°)2, -(CH^^-C^R0, -C(=N-OR°)-N(R°)2, -O-(CH2)0-6-SO2N(R°)2, -(CH2)1-6NHC(O)R°, and -SO2N(R°)2 wherein the two R°s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur; each R7 is independently selected from the group consisting of halogen, -CF3, -R°, -OR0, -OCF3, -(CHs e-OR0, -SR°, -SCF3, -(CH2)ι-6-SR0, aryl optionally substituted by R6, methylenedioxy, ethylenedioxy, -NO2, -CN, -(CH2)ι-6-CN, -N(R°)2, -(CH2)1-6-N(R°)2, -NR°C(O)R°, -NR°(CN), -NR°C(O)N(R°)2, -N(R°)C(S)N(R°)2, -NR°CO2R°, -NR0NR°C(O)R°, -NR0NR°C(O)N(R°)2, -NR°NR0CO2R0, -C(O)C(O)R°, -C(O)CH2C(O)R°, -(CH2)o-6-CO2R°, -C(O)R°, -C(O)N(R°)N(R°)2, -C(O)N(R°)2, -C(O)N(R°)OH, -OC(O)R°, -C(O)N(R°)SO2R°, -OC(O)N(R°)2, -S(O)tR°, -S(O)t-OR0, -S(O)tN(R°)C(O)R°, -S(O)tN(R0)OR°, -NR°SO2N(R°)2, -NR°SO2R°, -C(=S)N(R°)2, -C(=NH)-N(R°)2, -(CH^-e-CtC R0, -C(=N-OR°)-N(R°)2, -O-(CH2)0-6-SO2N(R0)2, -(CH2)ι-6-NHC(O)R°, and -SO2N(R°)2 wherein the two R°s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur; each R8 independently is selected from the group consisting of R7, =O, =S, =N(R°), and =N(CN); R9 is hydrogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, cycloalkyl optionally substituted by one or more R8, heterocyclyl optionally substituted by one or more R8, heteroaryl optionally substituted by one or more R6, or aryl optionally substituted by one or more R6; or -(Y)m-R3 and R9 may combine with the nitrogen atom with which they are attached to form a saturated, partially saturated, or aromatic 5-7 membered monocyclic or 8-10 membered bicyclic ring that optionally contains 1 to 3 additional heteroatoms selected oxygen, phosphorus, sulfur, or nitrogen, wherein said ring may be optionally substituted with one or more R8; R10 is hydrogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, cycloalkyl optionally substituted by one or more R8, heterocyclyl optionally substituted by one or more R8, heteroaryl optionally substituted by one or more R6, or aryl optionally substituted by one or more R6; each R° is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, and heterocyclylalkyl, wherein each member of R° except H is optionally substituted by one or more R*, OR*, N(R*)2, =O, =S, halogen, CF3, NO2, CN, -C(O)R*, -CO2R*, -C(O)-aryl, -C(O)-heteroaryl, -C(O)aralkyl, -S(O)t-aryl, -S(O)t-heteroaryl, -NR*SO2R*, -NR*C(O)R*, -NR*C(O)N(R*)2> -N(R*)C(S)N(R*)2l
-NR*CO2R*, -NR*NR*C(O)R*, -NR*NR*C(O)N(R*)2, -NR*NR*CO2R*, -C(O)C(O)R*, -C(O)CH2C(O)R*, -C(O)N(R*)N(R*)2, -C(O)N(R*)2, -C(O)NR*SO2R*, -OC(O)N(R*)2, -S(O)tR*, -NR*SO2N(R*)2, -SO2N(R*)2 wherein the two R*s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur; and each R* is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl.
In one embodiment, suitably R10 is optionally substituted aryl, such as optionally substituted phenyl.
In one embodiment, R1 is
Figure imgf000007_0001
In one embodiment R9 is alkyl and preferably R9 is methyl.
In one embodiment -(Y)m-R3 suitably is
Figure imgf000007_0002
More suitably -(Y)m-R is
Figure imgf000008_0001
Figure imgf000009_0001
Figure imgf000010_0001
Figure imgf000011_0001
In another embodiment -(Y)m-R3 and -R9 combine with the nitrogen atom to which they are attached to form
Figure imgf000012_0001
Figure imgf000012_0002
In one embodiment R1 is selected from
Figure imgf000012_0003
In one embodiment X is -(CH2)-, -(CH2-CH2)-, or -(CH2-CH2-CH2)-. Suitably X is optionally substituted by one or more halogen or oxo. Further X optionally has 1-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen.
In one embodiment the A ring is selected from the following, where the asterisk (*) indicates the preferred, but not limiting, point(s) of substitution:
Figure imgf000013_0001
Figure imgf000013_0002
N γ- or y \ / \
N-^
Suitably each R2, with the asterisk (*) indicating a preferred, but not limiting, point of substitution from Ring A, independently is selected from
Figure imgf000014_0001
*-x y * - *y$ 'Xi *-& -A -A
Figure imgf000014_0002
Figure imgf000015_0001
Figure imgf000016_0001
In one embodiment the ring A, with two geminal R2s, is selected from:
Figure imgf000017_0001
Suitably the A ring is tropane or piperidine, either optionally substituted with one or more R2. Preferrably, A--R2 is comprised of one of the following:
Figure imgf000017_0002
Figure imgf000018_0001
Figure imgf000018_0003
Figure imgf000018_0002
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
In one embodiment the A ring contains at least one additional nitrogen atom and said A ring optionally is N-substituted. Suitably the A ring is N-substituted with -(CH2)a-(Vb-R+).
Another aspect of the present invention includes a method of treatment including prevention of a viral infection in a mammal comprising administering to said mammal an antiviral effective amount of a compound of the present invention. Preferably the viral infection is an HIV infection.
Another aspect of the present invention includes a method of treatment including prevention of a bacterial infection in a mammal comprising administering to said mammal an effective amount of a compound of the present invention. Preferably the bacterium is Yersinia pestis.
Another aspect of the present invention includes a method of treatment including prevention of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders in a mammal comprising administering to said mammal a pharmaceutically effective amount of a compound of the present invention.
Another aspect of the present invention includes a compound of the present invention for use in medical therapy.
Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a viral infection. Preferably the viral infection is a HIV infection.
Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a bacterial infection. Preferably the bacterium is Yersinia pestis.
Another aspect of the present invention includes the use of a compound of the present invention in the manufacture of a medicament for the treatment including prophylaxis of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders.
Another aspect of the present invention includes a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the present invention together with a pharmaceutically acceptable carrier. Preferably the pharmaceutical composition is in the form of a tablet, a capsule, or a liquid.
Another aspect of the present invention includes a method of treatment including prevention of a viral infection in a mammal comprising administering to said mammal a composition comprising a compound of the present invention and another therapeutic agent. Preferably the composition comprises one or more therapeutic agent selected from the group consisting of (1 -alpha, 2-beta, 3-alpha)-9-[2,3- bis(hydroxymethyl) cyclobutyljguanine [(-)BHCG, SQ-34514, lobucavir], 9- [(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir, acyclic nucleoside phosphonates, (S)-1 -(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene] bis(oxymethylene)-2,2-dimethylpropanoic acid (bis-POM PMEA, adefovir dipivoxil), [[(1 R)-2-(6-amino-9H-purin-9-yl)-1 -methylethoxy]methyl]phosphonic acid (tenofovir), (R)-[[2-(6-Amino-9H-purin-9-yl)-1 -methylethoxy]methyl]phosphonic acid bis- (isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA), ribonucleotide reductase inhibitors, 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone and hydroxyurea, nucleoside reverse transcriptase inhibitors, 3'-azido-3'- deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'- dideoxyadenosine, 2',3'-dideoxyinosine (ddl, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)-beta-D-2,6-diaminopurine dioxolane (DAPD), 3'-azido-2',3'- dideoxythymidine-5'-H-phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), (-)-cjs-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'- fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol (abacavir), 9-[4- hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G) ribavirin, protease inhibitors, indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, fosamprenavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5- yloxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5- dimethyl-1,3- thiazolidine-4-carboxamide (KNI-272), 4R-(4alpha,5alpha,6beta)]-1 ,3-bis[(3- aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3- diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5- trifluoromethylpyridinyl)-sulfonylamino]phenyl]propyl]-4- hydroxy-δalpha-phenethyl- 6beta-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N- (methoxycarbonyl)-l-tert-leucylamino]-4- phenylbutyl-N alpha-(methoxycarbonyl)-N'- [4-(2-pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3- hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2- methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)-hydroxy-1 (S)- indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(1-(4-benzo[b]furanylmethyl)-2(S)-N'- (tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A), interferons, α-interferon, renal excretion inhibitors, probenecid, nucleoside transport inhibitors, dipyridamole, pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin, phosphonoformic acid, immunomodulators, interleukin II, thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD4 and genetically engineered derivatives thereof, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (BI-RG-587), alpha-((2-acetyl-5-methylphenyl)amino)-2,6- dichloro-benzeneacetamide (loviride), 1 -[3-(isopropylamino)-2-pyridyl]-4-[5- (methanesulfonamido)-l H-indol-2-ylcarbonyl]piperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12-hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11 ,12- dihydro-2H, 6H, 10H-benzo(1 , 2-b:3, 4-b':5, 6-b")tripyran-2-one ((+) calanolide A), , (4S)-6-Chloro-4-[1 E)-cyclopropylethenyl)-3,4- dihydro-4-(trifluoromethyl)-2(1 H)- quinazolinone (DPC-083), (S)-6-chloro-4-(cyclopropylethynyl)-1 ,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one (efavirenz, DMP 266), 1-(ethoxymethyl)-5- (1-methylethyl)-6-(phenylmethyl)-2,4(1 H,3H)-pyrimidinedione (MKC-442), and 5- (3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1 H-imidazol-2-ylmethyl carbamate (capravirine), glycoprotein 120 antagonists, PRO-2000, PRO-542, 1 ,4- bis[3-[(2, 4- dichlorophenyl)carbonylamino]-2-oxo-5,8-disodiumsuIfanyl]naphthalyl-2, 5-dimethoxyphenyl-1 , 4-dihydrazone (FP-21399), cytokine antagonists, reticulose (Product-R), 1,1'-azobis-formamide (ADA), 1 ,11-(1 ,4-phenylenebis(methylene))bis- 1 ,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD-3100), integrase inhibitors, and fusion inhibitors.
Another aspect of the present invention includes a method of treatment or prevention of a viral infection in a mammal comprising administering to said mammal a composition comprising a compound of the present invention and ritonavir.
Particular compounds of the present invention include:
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
C iral
Figure imgf000028_0001
Figure imgf000028_0002
Chiral
Chiral
Figure imgf000028_0003
Chiral
Figure imgf000028_0004
Chiral
Figure imgf000029_0001
Chiral
Chiral
Chiral
Figure imgf000029_0002
Chiral
Figure imgf000029_0003
Chiral
Figure imgf000030_0001
Figure imgf000030_0002
Chiral
iral
iral
Figure imgf000030_0003
Chiral
Figure imgf000031_0001
Chiral
Figure imgf000031_0002
Figure imgf000031_0003
Chiral
Chiral
Chiral
Figure imgf000032_0001
Chiral
Figure imgf000032_0002
Chiral
Figure imgf000033_0001
Figure imgf000033_0002
Chiral
Figure imgf000033_0003
Figure imgf000033_0004
Chiral
Figure imgf000033_0005
Figure imgf000034_0001
Figure imgf000035_0001
DETAILED DESCRIPTION OF THE INVENTION
The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term "(un)substituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other. The term "alkyl", alone or in combination with any other term, refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
The term "cycloalkyl", "carbocylyl", "carbocyclic", or "carbocycle", or "carbocyclo", alone or in combination with any other term, refers to a monocyclic or polycyclic non-aromatic hydrocarbon ring radical having three to twenty carbon atoms, preferably from three to twelve carbon atoms, and more preferably from three to ten carbon atoms. If polycyclic, each ring in a carbocylyl radical is non-aromatic unless otherwise indicated. A carbocylyl radical is either completely saturated or contains one or more units of unsaturation but is not aromatic. The unsaturation, if present, may occur in any point in the ring that may result in any chemically stable configuration. The term "cycloalkyl", "carbocylyl", "carbocyclic", or "carbocycle", or "carbocyclo" also includes hydrocarbon rings that are fused to one or more aromatic rings, such as in tetrahydronaphthyl, where the radical or point of attachment is on the non-aromatic ring.
Unless otherwise indicated, the term "cycloalkyl", "carbocylyl", "carbocyclic", or "carbocycle", or "carbocyclo" also includes each possible positional isomer of a non-aromatic hydrocarbon radical, such as in 1-decahydronaphthyl, 2- decahydronaphthyl, 1 -tetrahydronaphthyl and 2-tetrahydronaphthyl. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, decahydronaphthyl, tetrahydronaphthyl and the like.
The term "alkenyl," alone or in combination with any other term, refers to a straight-chain or branched-chain alkyl group with at least one carbon-carbon double bond. Examples of alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, hexadienyl and the like.
The term "alkynyl" refers to hydrocarbon groups of either a straight or branched configuration with one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, butynyl, pentynyl, and the like.
The term "alkoxy" refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert- butoxy and the like.
The term "aryl", alone or in combination with any other term, refers to an aromatic monocyclic or polycyclic hydrocarbon ring radical containing five to twenty carbon atoms, preferably from six to fourteen carbon atoms, and more preferably from six to ten carbon atoms. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic hydrocarbon ring is fused to one or more non-aromatic carbocyclic or heteroatom-containing rings, such as in an indanyl, phenanthridinyl or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic hydrocarbon ring.
Unless otherwise indicated, the term "aryl" also includes each possible positional isomer of an aromatic hydrocarbon radical, such as in 1-naphthyl, 2- naphthyl, 5-tetrahydronaphthyl, 6-tetrahydronaphthyl, 1 -phenanthridinyl, 2- phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 7-phenanthridinyl, 8- phenanthridinyl, 9-phenanthridinyl and 10-phenanthridinyl. Examples of aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like.
The term "aralkyl" further refers to groups of -RaRb, where Ra is an alkylene as defined herein and Rb is an aryl as defined herein.
The term "heterocycle", "heterocyclic", and "heterocyclyl", alone or in combination with any other term, refers to a non-aromatic monocyclic or polycyclic ring radical containing three to twenty carbon atoms, preferably three to seven carbon atoms if monocyclic and eight to eleven carbon atoms if bicyclic, and in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, and S. If polycyclic, each ring in a heterocyclyl radical is non-aromatic unless otherwise indicated. A heterocyclic ring may be fully saturated or may contain one or more units of unsaturation but is not aromatic. The unsaturation, if present, may occur in any point in the ring that may result in any chemically stable configuration. The heterocyclic ring may be attached at a carbon or heteroatom that results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles.
Also included within the scope of the term "heterocycle", "heterocyclic", or "heterocyclyl" is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring. Unless otherwise indicated, the term "heterocycle", "heterocyclic", or "heterocyclyl" also includes each possible positional isomer of a heterocyclic radical, such as in 1-decahydroquinoline, 2-decahydroquinoline, 3- decahydroquinoline, 4-decahydroquinoline, 5-decahydroquinoline, 6- decahydroquinoline, 7-decahydroquinoline, 7-decahydroquinoline, 8- decahydroquinoline, 4a-decahydroquinoline, 8a-decahydroquinoline, 1 -indolinyl, 2- indolinyl, 3-indolinyl, 1-tetrahydroquinoline, 2-tetrahydroquinoline, 3- tetrahydroquinoline and 4-tetrahydroquinoline. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl.
Examples of heterocyclic groups include, but are not limited to, imidazolinyl, 2,3-dihydro-1 H-imidazolyl, imidazolidinyl, indazolinolyl, perhydropyridazyl, pyrrolinyl, pyrrolidinyl, 4H-pyrazoIyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, morpholinyl, thiamorpholinyl, thiazolidinyl, thiamorpholinyl, oxopiperidinyl, oxopyrrolidinyl, azepinyl, tetrahydrofuranyl, oxoazepinyl, tetrahydropyranyl, thiazolyl, dioxolyl, dioxinyl, oxathiolyl, benzodioxolyl, dithiolyl, dithiolanyl, tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl, tetahydrofurodihydrofuranyl, dihydropyranyl, tetrahydropyranodihydrofuranyl, tetradyrofurofuranyl, tetrahydropyranofuranyl, diazolonyl, phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl and benzothianyl.
The term "heteroaryl", alone or in combination with any other term, refers to an aromatic monocyclic or polycyclic ring radical containing five to twenty carbon atoms, preferably five to ten carbon atoms, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, and S. Preferred heteroaryl groups include 5-6 membered monocyclic heteroaryls and 8-10 membered bicyclic heteroaryls.
Also included within the scope of the term "heteroaryl" is a group in which a heteroaromatic ring is fused to one or more aromatic or non-aromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include, but are not limited to, pyrido[3,4-d]pyrimidinyl, 7,8-dihydro-pyrido[3,4-d]pyrimidine and 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidine. Unless otherwise indicated, the term "heteroaryl" also includes each possible positional isomer of a heteroaryl radical, such as in 2-pyrido[3,4-d]pyrimidinyl and 4-pyrido[3,4-d]pyrimidinyl.
Examples of heteroaryl groups include, but are not limited to, imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl, pyridyl, pyrrolyl, pyrazolyl, pyrazinyl, quinoxalyl, pyrimidinyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, carbazolyl, carbolinyl, tetrazolyl, benzofuranyl, oxazolyl, benzoxazolyl, isoxozolyl, isothiazolyl, thiadiazolyl, furazanyl, oxadiazolyl, benzimidazolyl, benzothienyl, quinolinyl, benzotriazolyl, benzothiazolyl, isoquinolinyl, isoindolyl, acridinyl and benzoisoxazolyl.
The term "heteroaralkyl" further refers to groups of -RaRb, where Ra is an alkylene as defined herein and R is a heteroaryl as defined herein.
The term "heteroatom" means nitrogen, oxygen, phosphorus, or sulfur and includes any oxidized forms thereof, including as non-limiting examples oxidized forms of nitrogen such as N(O) {N+-O"}, oxidized forms of sulfur such as S(O) and S(O)2, and the quatemized form of any basic nitrogen.
The term "halogen" refers to fluorine, chlorine, bromine or iodine.
The term "pharmaceutically effective amount" refers to an amount of a compound of the invention that is effective in treating a CCR5-related disease, for example a virus infection, for example an HIV infection, in a patient either as monotherapy or in combination with other agents. The term "treatment" as used herein refers to the alleviation of symptoms of a particular disorder in a patient, or the improvement of an ascertainable measurement associated with a particular disorder, and may include the suppression of symptom recurrence in an asymptomatic patient such as a patient in whom a viral infection has become latent. The term "prophylaxis" refers to preventing a disease or condition or preventing the occurrence of symptoms of such a disease or condition, in a patient. As used herein, the term "patient" refers to a mammal, including a human.
The term "pharmaceutically acceptable carrier" refers to a carrier that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the therapeutic agent.
The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
Pharmaceutically acceptable salts of the compounds according to the invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicyclic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium, NW4 + (wherein W is C1-4 alkyl) and other amine salts. Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+, NH +, and NW4 + (wherein W is a C1-4alkyl group).
Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof.
Salts of the compounds of the present invention may be made by methods known to a person skilled in the art. For example, treatment of a compound of the present invention with an appropriate base or acid in an appropriate solvent will yield the corresponding salt.
Esters of the compounds of the present invention are independently selected from the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted by, for example, halogen, C^alkyl, or C-^alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a Cι-20 alcohol or reactive derivative thereof, or by a 2,3-di (C6-24)acyl glycerol.
In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms, Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group. The compounds according to the invention contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereoisomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisioned.
Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are also within the scope of this invention.
Certain compounds of this invention may exist in alternative tautomeric forms. All such tautomeric forms of the present compounds are within the scope of the invention. Unless otherwise indicated, the representation of either tautomer is meant to include the other.
The present invention features compounds according to the invention for use in medical therapy, for example for the treatment including prophylaxis of viral infections such as an HIV infections and associated conditions. Reference herein to treatment extends to prophylaxis as well as the treatment of established infections, symptoms, and associated clinical conditions such as AIDS related complex (ARC), Kaposi's sarcoma, and AIDS dementia.
The present invention features use of the compounds of the present invention in the manufacture of a medicament for the treatment including prophylaxis of a CCR5-related disease or condition, for example, a viral infection, for example, an HIV infection.
According to another aspect, the present invention provides a method for the treatment including prevention of the symptoms or effects of a viral infection in an infected animal, for example, a mammal including a human, which comprises treating said animal with a pharmaceutically effective amount of a compound according to the invention. According to one aspect of the invention, the viral infection is a retroviral infection, in particular an HIV infection. A further aspect of the invention includes a method for the treatment including prevention of the symptoms or effects of an HBV infection.
The compounds according to the invention may also be used in adjuvant therapy in the treatment of HIV infections or HIV-associated symptoms or effects, for example Kaposi's sarcoma.
The compounds of the present invention may also be used in the treatment including prevention of other CCR5-related diseases and conditions, including multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis, immune mediated disorders.
The present invention further provides a method for the treatment of a clinical condition in an animal, for example, a mammal including a human which clinical condition includes those which have been discussed hereinbefore, which comprises treating said animal with a pharmaceutically effective amount of a compound according to the invention. The present invention also includes a method for the treatment including prophylaxis of any of the aforementioned diseases or conditions.
In yet a further aspect, the present invention provides the use of a compound according to the invention in the manufacture of a medicament for the treatment including prophylaxis of any of the above mentioned viral infections or conditions.
The above compounds according to the invention and their pharmaceutically acceptable derivatives may be employed in combination with other therapeutic agents for the treatment (including prevention) of the above infections or conditions. Combination therapies according to the present invention comprise the administration of a compound of the present invention or a pharmaceutically acceptable derivative thereof and another pharmaceutically active agent. The active ingredient(s) and pharmaceutically active agents may be administered simultaneously in either the same or different pharmaceutical compositions or sequentially in any order. The amounts of the active ingredient(s) and pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
Examples of such therapeutic agents include agents that are effective for the treatment of viral infections or associated conditions. Among these agents are (1- alpha, 2-beta, 3-alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ- 34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, for example acyclovir, valaciclovir, famciclovir, ganciclovir, and penciclovir, acyclic nucleoside phosphonates, for example (S)-1-(3- hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9- yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene)-2,2-dimethylpropanoic acid (bis- POM PMEA, adefovir dipivoxil), [[(1 R)-2-(6-amino-9H-purin-9-yl)-1- methylethoxyjmethyljphosphonic acid (tenofovir), and (R)-[[2-(6-Amino-9H-purin-9- yl)-1 -methylethoxyjmethyljphosphonic acid bis-(isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA), ribonucleotide reductase inhibitors, for example 2-acetylpyridine 5- [(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone and hydroxyurea, nucleoside reverse transcriptase inhibitors, for example 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'-dideoxyadenosine, 2',3'- dideoxyinosine (ddl, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)-beta- D-2,6-diaminopurine dioxolane (DAPD), S'-azido^'.S'-dideoxythymidine-δ'-H- phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), (-)-cis-1-(2- hydroxymethyl)~1 ,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2- (hydroxymethyl)-l ,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'- fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6- (cycIopropylamino)-9JH-purin-9-yl]-2-cyclopentene-1 -methanol (abacavir), 9-[4- hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G) and ribavirin, protease inhibitors, for example indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, fosamprenavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N- (isoquinolin-5-yloxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5- dimethyl-1 ,3-thiazolidine-4-carboxamide (KNI-272), 4R-(4alpha,5alpha,6beta)]-1 ,3- bis[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1 ,3- diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5- trifluoromethylpyridinyl)-sulfonylamino]phenyl]propyl]-4- hydroxy-6alpha-phenethyl- 6beta-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N- (methoxycarbonyI)-l-tert-leucylamino]-4- phenylbutyl-N alpha-(methoxycarbonyl)-N'-[4- (2-pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3- hydroxy-2-methylbenzamido)-4-phenyIbutanoyl)-5,5-dimethyl-N-(2- methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)-hydroxy-1 (S)- indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(1-(4-benzo[b]furanylmethyl)-2(S)-N'- (tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A), interferons such as α- interferon, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyridamole; pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin, phosphonoformic acid, as well as immunomodulators such as interleukin II or thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD4 and genetically engineered derivatives thereof, non- nucleoside reverse transcriptase inhibitors (NNRTIs), for example nevirapine (BI-RG- 587), alpha-((2-acetyl-5-methyIphenyl)amino)-2,6-dichloro-benzeneacetamide (loviride), 1 -[3-(isopropylamino)-2-pyridyl]-4-[5-(methanesulfonamido)-1 H-indol-2- ylcarbonyljpiperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12- Hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11 ,12-dihydro-2H, 6H, 10H-benzo(1 , 2-b:3, 4-b':5, 6-b")tripyran-2-one ((+) calanolide A), (4S)-6-Chloro-4-[1 E)- cyclopropylethenyl)-3,4- dihydro-4-(trifluoromethyl)-2(1 H)-quinazolinone (DPC-083), (S)-6-chloro-4-(cyclopropylethynyl)-1 ,4-dihydro-4-(trifluoromethyl)-2H-3,1- benzoxazin-2-one (efavirenz, DMP 266), 1-(ethoxymethyl)-5-(1-methylethyl)-6- (phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-442), and 5-(3,5- dichlorophenyl)thio-4-isopropyI-1 -(4-pyridyl)methyl-1 H-imidazoI-2-ylmethyl carbamate (capravirine), glycoprotein 120 antagonists, for example PRO-2000, PRO-542 and 1 ,4-bis[3-[(2, 4- dichlorophenyl)carbonylamino]-2-oxo-5,8- disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1 , 4-dihydrazone (FP-21399), cytokine antagonists, for example reticulose (Product-R), 1 ,1'-azobis-formamide (ADA), 1 ,11-(1 ,4-phenyIenebis(methylene))bis-1 ,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD-3100), integrase inhibitors, or fusion inhibitors, for example T-20 and T-1249. The present invention further includes the use of a compound according to the invention in the manufacture of a medicament for simultaneous or sequential administration with at least another therapeutic agent, such as those defined hereinbefore.
Compounds of the present invention may be administered with an agent known to inhibit or reduce the metabolism of compounds, for example ritonavir. Accordingly, the present invention features a method for the treatment including prophylaxis of a disease as hereinbefore described by administration of a compound of the present invention in combination with a metabolic inhibitor. Such combination may be administered simultaneously or sequentially.
In general a suitable dose for each of the above-mentioned conditions will be in the range of 0.01 to 250 mg per kilogram body weight of the recipient (e.g. a human) per day, preferably in the range of 0.1 to 100 mg per kilogram body weight per day and most preferably in the range 0.5 to 30 mg per kilogram body weight per day and particularly in the range 1.0 to 20 mg per kilogram body weight per day. Unless otherwise indicated, all weights of active ingredient are calculated as the parent compound of formula (I); for salts or esters thereof, the weights would be increased proportionally. The desired dose may be presented as one, two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In some cases the desired dose may be given on alternative days. These sub- doses may be administered in unit dosage forms, for example, containing 10 to 1000 mg or 50 to 500 mg, preferably 20 to 500 mg, and most preferably 50 to 400 mg of active ingredient per unit dosage form.
While it is possible for the active ingredient to be administered alone it is preferable to present it as a pharmaceutical composition. The compositions of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be acceptable in the sense of being compatible with the other ingredients of the composition and not injurious to the patient. Phamaceutical compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and intravitreal) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier, which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
The present invention further includes a pharmaceutical composition as hereinbefore defined wherein a compound of the present invention or a pharmaceutically acceptable derivative thereof and another therapeutic agent are presented separately from one another as a kit of parts.
Compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 25%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis as generally described in Pharmaceutical Research 3 (6), 318 (1986).
Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
Pharmaceutical compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Pharmaceutical compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray Pharmaceutical compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Pharmaceutical compositions for rectal administration may be presented as a suppository with a suitable carrier comprising, for example, cocoa butter or a salicylate or other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in molds.
Pharmaceutical compositions suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti- oxidants, buffers, bacteriostats and solutes which render the pharmaceutical composition isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The pharmaceutical compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Unit dosage pharmaceutical compositions include those containing a daily dose or daily subdose of the active ingredients, as hereinbefore recited, or an appropriate fraction thereof.
It should be understood that in addition to the ingredients particularly mentioned above the pharmaceutical compositions of this invention may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
EXAMPLES
The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way.
Low resolution, open-access LC-MS data were acquired in either ESI pos/neg or APCI pos/neg mode with scanning from 100-1100 amu @ 0.5 sec/scan. LC conditions: flowrate 0.8 mL/min. 85% H2O (0.1% formic acid) to 100% MeOH (0.075% formic acid) in 6 minutes. Phenomenex Max-RP column, 2.0x50 mm.
High Resolution Mass Spectra were acquired using Micromass LCT mass spectrometer (time-of-flight) with flow injection (FIA-MS) at 0.3 mL/min with 100% MeOH (0.1% formic acid), run time of 2 minutes, in ESI+ mode, scanning from 100- 1100 amu @ 0.5 sec/scan. Reserpine was used as the lock mass (m/z 609.2812) and to adjust mass scale. As will be appreciated by those skilled in the art, the following schemes may be followed in preparing the compounds of the present invention. The variability depicted within the scheme(s) illustrated herein, for example the variability of the "R" groups, should be limited to the particular scheme and not necessarily extended throughout the rest of the present specification. Scheme 1 :
Figure imgf000050_0001
Where:
= an acid chloride or a sulfonyl chloride
Figure imgf000050_0002
R2-X = an alkyl halide
Figure imgf000050_0003
Preparation 1 : (4R)-4-hydroxy-2-phenyl-5-[(phenylmethyI)oxy]pentanenitrile
Figure imgf000050_0004
Phenylacetonitrile (4.59g, 39.2mmol) and (2S)-2-hydroxy-3-[(phenylmethyl)oxy]propyI 4-methylbenzenesulfonate (13.20g, 39.2mmol, 1eq) were dissolved in 50mL THF, cooled to -78°C, and treated with 2.5M butyllithium in hexanes (35mL, 86.3mmol, 2.2eq) added dropwise over 30min. The reaction mixture was stirred 4h at -78°C, allowed to warm to ambient temperature and stirred an additional 16h. The reaction mixture was diluted with EtOAc, washed successively with water and brine, dried over MgSO4, filtered and concentrated to give the diastereomeric product as an orange oil in quantitative yield which was carried on without purification. ES-LCMS m/z 304.33 (M+Na).
Preparation 2: (1R)-3-cyano-3-phenyl-1-{[(phenylmethyl)oxy]methyl}propyl 4- methylbenzenesulfonate
Figure imgf000051_0001
(4R)-4-hydroxy-2-phenyl-5-[(phenylmethyl)oxy]pentanenitrile (16.0g, 57mmol), accessed via the method of preparation 1, was dissolved in 116mL CHCI3 and 116mL Pyridine (25eq) with DMAP (0.70g, 5.7mmol, 0.1 eq) and cooled to 0°C. 4- methylbenzenesulfonyl chloride (43.5g, 228mmol, 4eq) was added to the reaction mixture and stirred 3 days at 0°C. The reaction mixture was washed successively with 1 N HCI (4 x 250mL) and brine, dried over MgSO4, filtered and concentrated to a red oil. The crude material was purified by flash chromatography (SiO2, 10- 25% EtOAc/Hexanes) to give the diastereomeric product as a yellow oil (14.88g, 34.2mmol, 60%). ES-LCMS m/z 458.36 (M+Na).
Preparation 3A: (1S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile
Figure imgf000051_0002
To (1f?)-3-cyano-3-phenyl-1-{[(phenylmethyl)oxy]methyl}propyl 4- methylbenzenesulfonate (7.4g, 17.0mmol), accessed via the method of preparation 2, in 70mL DMF at -42°C was added 1 M lithium bis(trimethylsilyl)amide in hexanes (25.5mL, 25.5mmol, 1.5eq) dropwise and stirred with continued cooling at -42°C for 1 h. The reaction mixture was diluted with EtOAc, washed successively with water (4x) and brine, dried over MgSO4, filtered and concentrated to give the title compound (4.25g, 16.1mmol, 95%) as a yellow oil which was shown to be a 94:6 mix of the title compound to the product of Preparation 3B. 1H NMR (300 MHz, CDCI3) δ 7.42-7.29 (m, 10H), 4.64 (m, 2H), 3.91-3.86 (m, 1H), 3.74-3.68 (m,1H), 2.00-1.90 (m, 1 H), 1.68-1.56 (m, 2H).
Preparation 3B: (1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile
Figure imgf000052_0001
To 765mL toluene cooled to 0°C was added 1.0 M LHMDS in hexanes (148.1 mL, 148.1 mmol, 1 eq). To this solution was added (1R)-3-cyano-3-phenyl-1- {[(phenylmethyl)oxy]methyl}propyl 4-methylbenzenesulfonate (43.0 g, 98.73 mmol, 1eq), accessed via the method of Preparation 2, in 236mL toluene. The reaction mixture was stirred at 0°C for 16h, then washed successively with water and brine, dried over MgSO4, filtered and concentrated to give a yellow oil that was shown to be an 8:2 diastereomeric mixture of the title compound to the product of Preparation 3A. The desired diastereomer (16.0 g, 62%) was separated by silica gel flash chromatography using 9:1 → 8:2 hexanes in ethyl acetate. 1H NMR (300 MHz, CDCI3) δ 7.44-7.15 (m, 10H), 4.28-4.19 (m, 2H), 3.31-3.27 (m, 1H), 2.94-2.84 (m, 1 H), 2.22-2.15 (m,1H), 1.76-1.72 (m, 1H), 1.47-1.44 (m, 1H). ES-LCMS m/z 264.1 (M+H).
Preparation 4A: [((1S,2r?)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine
Figure imgf000053_0001
To 16.2mL 1 M lithium aluminum hydride(16.2mmol) in diethyl ether at 0°C (1 S.2R)- 1-phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile (4.25g, 16.2mmol), accessed via the method of Preparation 3A, dissolved in 17mL diethyl ether. After complete addition, the reaction mixture was stirred at 0°C for 2h followed by 4h at ambient temperature. The reaction mixture was diluted with 360mL diethyl ether and quenched with successive addition of 0.6mL water, 0.6mL 15% NaOH, and 3.0mL water. The reaction mixture was filtered and the filtrate was concentrated to a clear oil. The oil was purified by flash chromatography (SiO2, 3->5%CH3OH/ EtOAc with 1%NH4OH) to give the title product (3.08g, 11.5mmol, 71%) as a single diastereomer. 1H NMR (300 MHz, CDCI3) δ 7.37-7.19 (m, 10H), 4.62-4.54 (m, 2H), 3.88 (m, 1 H), 3.34 (m, 1H), 2.96 (d, J = 14.1 Hz, 1 H), 2.70 (d, J = 14.1Hz, 1H), 1.58 (m, 1 H), 1.00 (m, 1H), 0.62 (m, 1 H). ES-LCMS m/z 268.4 (M+H).
Preparation 4B: [((1 R,2R)-1 -phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine
Figure imgf000053_0002
To 19.4mL 1M lithium aluminum hydride (19.4mmol) in diethyl ether at 0°C was added (1 f?,2R)-1 -phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile (5.10g, 19.4mmol), accessed via the method of Preparation 3B, dissolved in 20mL diethyl ether. After complete addition, the reaction mixture was stirred at 0°C for 3h. The reaction mixture was diluted with 360mL diethyl ether and quenched with successive addition of 0.6mL water, 0.6mL 15% NaOH, and 3.0mL water. The reaction mixture was filtered and the filtrate was concentrated to a clear oil. The oil was purified by flash chromatography (SiO2, 3-- 7%CH3OH/ EtOAc with 1%NH4OH) to give the title product (3.03g, 11.3mmol, 59%) as a single diastereomer. 1H NMR (300 MHz, CDCI3) δ 7.35-7.21 (m, 10H), 4.35-4.25 (m, 2H), 3.22-3.18 (m, 1 H), 3.00- 2.94 (m, 2H), 2.43 (d, J = 13.5Hz, 1H), 1.36 (m, 1H), 0.91 (m, 1H), 0.78 (m, 1 H). ES- LCMS m/z 268.4 (M+H).
Preparation 5A: Λ/-[((1S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide
Figure imgf000054_0001
[((1 S,2R)-1 -phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine (1.00g, 3.74mmol), accessed via the method of Preparation 4A, was dissolved in 10mL DCE and combined with polymer-bound diisopropylamine (4.49mmol, 1.2eq). Benzenesulfonyl chloride (1.06g, 5.98mmol, 1.6eq) was added and the reaction mixture agitated 16h at ambient temperature. Excess sulfonyl chloride was scavanged by addition of polymer-bound trisamine (4.49mmol, 1.2eq) with agitation at ambient temperature for 16h. The solid-supported reagents were filtered off, washed successively with DCM, CH3OH, THF, and DCM, the filtrates combined and concentrated to give the title product (1.52g, 100%) as an amber oil. 1H NMR (300 MHz, CDCI3) δ 8.04-8.02 (m, 1 H), 7.75-7.15 (m, 14H), 5.67 (m, 1 H), 4.55 (s, 2H), 3.90-3.86 (m, 1 H), 3.57-3.51 (m, 1 H), 3.12-3.07 (m, 1 H), 2.90-2.85 (m, 1 H), 1.62- 1.56 (m, 1 H), 1.03-0.99 (m, 1 H), 0.66 (m, 1 H). ES-LCMS m/z 430.1 (M+Na).
Preparation 5B: /V-[((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide
Figure imgf000054_0002
[((1 R,2R)-1 -phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine (1.00g, 3.74mmol), accessed via the method of preparation 4B, was dissolved in 10mL DCE and combined with polymer-bound diisopropylamine (4.49mmol, 1.2eq). Benzenesulfonyl chloride (1.06g, 5.98mmol, 1.6eq) was added and the reaction mixture agitated 16h at ambient temperature. Excess sulfonyl chloride was scavanged by addition of polymer-bound trisamine (4.49mmol, 1.2eq) with agitation at ambient temperature for 16h. The solid-supported reagents were filtered off, washed successively with DCM, CH3OH, THF, and DCM, the filtrates combined and concentrated to give the title product (1.52g, 100%) as an amber oil. 1H NMR (300 MHz, CDCI3) δ 8.04-8.02 (m, 1H), 7.64-7.19 (m, 14H), 5.25 (m, 1H), 4.23 (ABq, J = 35.5, 11.4Hz, 2H), 3.28-3.24 (m, 1 H), 3.15 (d, J = 12.7Hz, 1H), 2.90 (d, J = 12.7Hz, 1 H), 2.82-2.77 (m, 1H), 1.36-1.31 (m, 1 H), 0.96-0.92 (m, 1 H), 0.76 (m, 1 H). ES- LCMS m/z 430.2 (M+Na).
Preparation 6A: Λ/-methyl-N-[((1S,2R)-1-phenyI-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide
Figure imgf000055_0001
lodomethane (2.12g, 14.9mmol, 4eq) was added portionwise to Λ/-[((1S,2R)-1- phenyl-2-{[(phenylmethyl)oxy]methyl}cycIopropyl)methyl]benzenesulfonamide (1.71 g, 3.74mmol, 1eq), accessed via the method of preparation 5A, in 7mL DMF with potassium carbonate (1.03g, 7.48mmol, 2eq) over 6h at 80°C. Following addition, the reaction mixture was stirred 16h at 80°C. The reaction mixture was diluted with EtOAc, washed successively with saturated aqueous NaHCO3, water (4x) and brine, dried over MgSO4, filtered and concentrated to give a brown oil. The crude material was purified by flash chromatography (SiO2, eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (1.57g, 100%) as a yellow oil. 1H NMR (300 MHz, CDCI3) δ 7.58-7.19 (m, 15H), 4.57 (ABq, J = 24.3, 11.9Hz, 2H), 3.84-3.80 (m, 1 H), 3.58-3.48 (m, 1H), 3.29 (d, J = 14.1 Hz, 1 H), 2.50 (s, 3H), 1.47 (m, 1 H), 1.33 (m, 1 H), 0.91 (m, 1 H). ES-LCMS m/z 444.2 (M+Na).
Preparation 6B: Λ/-methyl-Λ/-[((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide
Figure imgf000056_0001
lodomethane (2.12g, 14.9mmol, 4eq) was added portionwise to Λ/-[((1R,2R)-1- phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide (1.71g, 3.74mmol, 1eq), accessed via the method of preparation 5B, in 7mL DMF with potassium carbonate (1.03g, 7.48mmol, 2eq) over 6h at 80°C. Following addition, the reaction mixture was stirred 16h at 80°C. The reaction mixture was diluted with EtOAc, washed successively with saturated aqueous NaHCO3, water (4x) and brine, dried over MgSO4, filtered and concentrated to give a brown oil. The crude material was purified by flash chromatography (SiO2, eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (1.57g, 100%) as a yellow oil. 1H NMR (300 MHz, CDCI3) δ 7.58-7.21 (m, 15H), 4.26 (ABq, J = 26.5, 11.7Hz, 2H), 3.50 (d, J = 14.0Hz, 1 H), 3.23-3.20 (m, 1 H), 2.94-2.89 (m, 2H), 2.54 (s, 3H), 1.39 (m, 1 H), 1.10 (m, 1 H), 0.92 (m, 1 H). ES-LCMS m/z 444.3 (M+Na).
Preparation 7A: Λ/-{[(1 S,2R)-2-(hydroxymethyl)-1-phenylcycIopropyl]methyl}-Λ/- methylbenzenesulfonamide
Figure imgf000056_0002
Λ-methyl-Λ/-[((1 S,2R)-1 -phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide (1.57g, 3.74mmol), accessed via the method of preparation 6A, was combined with 10% palladium on activated carbon (0.35g) in EtOAc and hydrogenated under 1atm H2(g) for 4h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to give the title product (1.17g, 3.53mmol, 95%) as a clear oil. 1H NMR (300 MHz, CDCI3) δ 7.68-7.18 (m, 10H), 4.07-4.03 (m, 1 H), 3.72-3.66 (m, 1 H), 3.55 (d, J = 14.1Hz, 1 H), 3.25 (d, J = 14.1Hz, 1 H), 2.36 (s, 3H), 1.59 (m, 1H), 1.18- 1.15 (m, 1 H), 0.79 (m, 1H). ES-LCMS m/z 354.3 (M+Na).
Preparation 7B: Λ/-{[(1R,2R)-2-(hydroxymethyl)-1-phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide
Figure imgf000057_0001
Λ,-methyl-Λ/-[((1 R,2R)-1 -phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]benzenesulfonamide (1.57g, 3.74mmol), accessed via the method of preparation 6B, was combined with 10% palladium on activated carbon (0.35g) in EtOAc and hydrogenated under 1atm H2(g) for 4h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to give the title product (1.01g, 3.05mmol, 82%) as a clear oil. 1H NMR (300 MHz, CDCI3) δ 7.63-7.61 (m, 2H), 7.53 (m, 1 H), 7.46-7.43 (m, 2H), 7.33- 7.24 (m, 5H), 3.60 (d, J = 13.8Hz, 1H), 3.40-3.35 (m, 1 H), 3.20-3.14 (m, 1 H), 2.92 (d, J = 13.8Hz, 1 H), 2.55 (s, 3H), 1.43 (m, 1 H), 1.10 (m, 1 H), 0.99 (m, 1 H). ES-LCMS m/z 354.2 (M+Na).
Preparation 8A: Λ/-{[(1 S,2R)-2-formyl-1-phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide
Figure imgf000057_0002
Λ/-{[(1 S,2R)-2-(hydroxymethyl)-1 -phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide (600mg, 1.82mmol), accessed via the method of preparation 7A, was dissolved in 18mL DCM with 270uL 2-methylpropan-2-ol and treated with Dess-Martin Periodinane (1.23g, 2.90mmol, 1.6eq) at ambient temperature for 16h. The reaction mixture was diluted with 42mL diethyl ether and treated with 22mL 1N NaOH at ambient temperature for 15min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted successively with DCM, EtOAc/hexanes (1 :4)) to the title product (270mg, 0.82mmol, 45%) as a colorless oil. 1H NMR (300 MHz, CDCI3) δ 9.82 (d, J = 3.8Hz, 1 H), 7.65-7.28 (m, 10H), 3.53-3.43 (m, 2H), 2.42 (s, 3H), 2.34-2.32 (m, 1H), 1.90- 1.87 (m, 1 H), 1.70-1.66 (m, 1H).
Preparation 8B: Λ/-{[(1 R,2R)-2-formyl-1 -phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide
Figure imgf000058_0001
Λ/-{[(1 R,2R)-2-(hydroxymethyl)-1 -phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide (600mg, 1.82mmol), accessed via the method of preparation 7B, was dissolved in 18mL DCM with 270uL 2-methylpropan-2-ol and treated with Dess-Martin Periodinane (1.23g, 2.90mmol, 1.6eq) at ambient temperature for 16h. The reaction mixture was diluted with 42mL diethyl ether and treated with 22mL 1N NaOH at ambient temperature for 15min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted successively with DCM, EtOAc/hexanes (1 :4)) to the title product (410mg, 1.24mmol, 69%) as a colorless oil. 1H NMR (300 MHz, CDCI3) δ 8.54 (d, J = 6.7Hz, 1 H), 7.65 (m, 2H), 7.55 (m, 1H), 7.47 (m, 2H), 7.31-7.23 (m, 5H), 3.50 (d, J = 14.3Hz, 1H), 3.09 (d, J = 14.3Hz, 1H), 2.52 (s, 3H), 2.15-2.08 (m, 1 H), 1.93 (m, 1H), 1.76- 1.73 (m, 1 H).
Preparation 9A: Λ/-{[(1 R,2S)-2-formyl-1 -phenylcyclopropyl]methyl}-/V- methylbenzenesulfonamide
Figure imgf000059_0001
Starting from phenylacetonitrile and (2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl 4- methylbenzenesulfonate and using the methods of Preparations 1, 2, 3A, 4A, 5A, 6A, 7A, and 8A sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 9B: Λ/-{[(1 S,2S)-2-formyl-1 -phenylcyclopropyl]methyl}-Λ/- methylbenzenesulfonamide
Figure imgf000059_0002
Starting from phenylacetonitrile and (2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl 4- methylbenzenesulfonate and using the methods of Preparations 1, 2, 3B, 4B, 5B, 6B, 7B, and 8B sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 10: Compounds of general formula:
Figure imgf000059_0003
To aldehydes (33mg, 100μmol), made according to the methods of preparations 8A, 8B, 9A, and 9B, dissolved in 2mL DCE were were added secondary amines (100μmol, 1eq) in 1mL DCM and treated with sodium triacetoxyborohydride (42mg, 200μmol, 2eq) at ambient temperature for 16h with continuous agitation. The reaction mixtures were each treated with 4mL saturated aqueous NaHCO3with agitation for 1h, the organic phases separated via filtration through hydrophobic frit tube assemblies, and the organic filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column
(19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Final products were obtained in moderate to good yields. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
The following demonstrate the above-referenced general scheme:
Example 1 : Λ/-[((1S,2R)-2-{[4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidin-1-yl]methyl}-1- phenylcyclopropyl)methyl]-Λ/-methylbenzenesulfonamide
Figure imgf000060_0001
A -{[(1 S,2R)-2-formyl-1-phenylcyclopropyl]methyl}-/V-methylbenzenesulfonamide and 4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidine (incorporating by reference as needed WO 00/39125) were reacted as per Preparation 10 to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ 7.69-7.55 (m, 5H), 7.36-7.18 (m, 10H), 4.08 (s, 2H), 3.91 (d, J = 13.2Hz, 1 H), 3.08-2.98 (m, 2H), 2.81 (d, J = 13.2Hz, 1 H), 2.84-2.78 (m, 1 H), 2.59-2.43 (m, 2H), 2.52 (s, 3H), 2.27-1.97 (m, 4H), 1.80-1.66 (m, 2H), 1.45-1.39 (m, 1 H), 1.09-0.99 (m, 1H), 0.80 (m, 1 H). ES-LCMS m/z 557.2 (M+H).
Example 2: Benzyl ethyl{1-[((1R,2S)-2-{[methyl(phenylsulfonyl)amino]methyl}-2- phenylcyclopropyl)methyl]piperidin-4-yl}carbamate
Figure imgf000061_0001
Λ/-{[(1 S,2R)-2-formyl-1 -phenylcyclopropyl]methyl}-/V-methylbenzenesulfonamide and benzyl ethyl(piperidin-4-yl)carbamate (incorporating by reference as needed Bioorg. and Med. Chem. Lett., 11(2001), 2475) were reacted as per Preparation 10 to give the title compound.
1H NMR (300 MHz, DMSO-d6) δ 7.70-7.56 (m, 5H), 7.40-7.17 (m, 10H), 5.09 (s, 2H), 3.88 (d, J = 13.3Hz, 1H), 3.75 (m, 1 H), 3.19 (q, J = 6.6Hz, 2H), 3.09-3.05 (m, 1 H), 2.91-2.87 (m, 1 H), 2.83 (d, J = 13.3Hz, 1 H), 2.58-2.52 (m, 1H), 2.52 (s, 3H), 2.44- 2.38 (m, 1H), 2.08-1.92 (m, 2H), 1.77-1.58 (m, 4H), 1.41-1.37 (m, 1H), 1.07 (t, J = 6.6Hz, 3H), 1.07-0.99 (m, 1 H), 0.78 (m, 1 H). ES-LCMS m/z 576.1 (M+H).
Example 3: /V-[((1S,2S)-2-{[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methyl}-1- phenylcyclopropyl)methyl]-Λ/-methylbenzenesulfonamide
Figure imgf000061_0002
Λ/-{[(1 S,2S)-2-formyl-1-phenylcyclopropyl]methyl}-/V-methylbenzenesulfonamide and 4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidine (incorporating by reference as needed WO 00/39125) were reacted as per Preparation 10 to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ 7.69-7.54 (m, 5H), 7.35-7.20 (m, 10H), 4.06 (s, 2H), 3.55 (d, J = 13.8Hz, 1 H), 2.97-2.85 (m, 1H), 2.78 (d, J = 13.8Hz, 1 H), 2.64-2.59 (m, 1H), 2.53 (s, 3H), 2.27-2.21 (m, 1H), 2.02-1.88 (m, 4H), 1.75-1.61 (m, 2H), 1.48-1.41 (m, 1 H), 1.17 (m, 1 H), 1.07-1.02 (m, 1 H), 0.93-0.89 (m, 1 H). ES-LCMS m/z 557.1 (M+H).
Example 4: benzyl ethyl{1-[((1S,2S)-2-{[methyl(phenylsulfonyl)amino]methyl}-2- phenylcyclopropyl)methyl]piperidin-4-yl}carbamate
Figure imgf000062_0001
Λ/-{[(1S,2S)-2-formyl-1-phenylcyclopropyl]methyl}-Λ/-methylbenzenesulfonamide and benzyl ethyl(piperidin-4-yl)carbamate (incorporating by reference as needed Bioorg. and Med. Chem. Lett., 11 (2001 ), 2475) were reacted as per Preparation 10 to give the title compound.
1H NMR (300 MHz, DMSO-d6) δ 7.67-7.55 (m, 5H), 7.39-7.21 (m, 10H), 5.07 (s, 2H), 3.67 (m, 1H), 3.57 (d, J = 13.3Hz, 1 H), 3.17 (q, J = 6.6Hz, 2H), 2.99-2.93 (m, 1H), 2.76 (d, J = 13.3Hz, 1 H), 2.75-2.68 (m, 1 H), 2.52 (s, 3H), 2.29-2.19 (m, 1 H), 1.87- 1.38 (m, 7H), 1.11 (m, 1H), 1.04 (t, J = 6.6Hz, 3H), 1.07-1.03 (m, 1H), 0.90 (m, 1H). ES-LCMS m/z 576.2 (M+H).
Example 5: Λ/-[((1 S,2R)-1-(3-chlorophenyl)-2-{[(3-exo)-3-(2-methyl-1H-benzimidazol- 1 -yl)-8-azabicyclo[3.2.1 ]oct-8-yl]methyl}cyclopropyl)methylj-/V- methylbenzenesulfonamide
Figure imgf000062_0002
Λ/-{[(1 S,2R)-1 -(3-chlorophenyl)-2-formylcyclopropyl]methyl}-/V- methylbenzenesulfonamide [made from (3-chlorophenyl)acetonitrile via the sequential methods of Preparations 1, 2, 3A, 4A, 5A, 6A, 7A, 8A] and 1-[(3-exo)-8- azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazoIe (incorporating by reference as needed WO 00/38680) were reacted as per Preparation 10 to give the title compound. ES-LCMS /z 589.6 (M+H).
Example 6: Λ/-{[(1 S,2R)-2-{[4-(3-benzyl-1 ,2,4-oxadiazol-5-yl)piperidin-1 -yl]methyl}-1 - (3-chIorophenyl)cyclopropyl]methyl}-Λ/-methylbenzenesulfonamide
Figure imgf000063_0001
Λ/-{[(1 S,2R)-1 -(3-chlorophenyl)-2-formylcyclopropyl]methyl}-/V- methylbenzenesulfonamide [made from (3-chlorophenyl)acetonitrile via the sequential methods of Preparations 1 , 2, 3A, 4A, 5A, 6A, 7A, 8A] and 4-(3-benzyl- 1 ,2,4-oxadiazol-5-yl)piperidine (incorporating by reference as needed WO 00/39125) were reacted as per Preparation 10 to give the title compound.
1H NMR (300 MHz, CD3OD) δ 7.70-7.53 (m, 5H), 7.36-7.23 (m, 9H), 4.07 (s, 2H), 3.83 (d, J = 14.0Hz, 1H), 3.39-3.16 (m, 4H), 3.09 (d, J = 14.0Hz, 1H), 2.78-2.61 (m, 3H), 2.57 (s, 3H), 2.28-2.21 (m, 2H), 2.07-1.94 (m, 2H), 1.53-1.48 (m, 1 H), 1.33-1.29 (m, 1 H), 1.00-0.96 (m, 1H). ES-LCMS m/z 591.5 (M+H).
Scheme 2:
Figure imgf000064_0001
Preparation 11 A: 1 ,1-dimethylethyl [((1S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate
Figure imgf000064_0002
To a solution of [((1S,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine (28.53g, 107mmol, 1eq), accessed via the method of preparation 4A, and triethylamine (11.9g, 117mmol, 1.1eq) in 380mL DCM cooled to 0°C was added di(fetf-butyl) dicarbonate (24.45g, 112mmol, 1.05eq). The resultant mixture was stirred 2h at 0°C followed by 16h at ambient temperature. The reaction mixture was diluted with DCM, washed successively with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated to give the title compound (39.3g, 107mmol, 100%) as an amber oil. 1H NMR (300 MHz, CDCI3) δ 7.43-7.17(m, 10H), 5.35 (d, J=7.8Hz, 1 H), 4.60 (m, 2H), 3.95 (m, 2H), 3.35 (t, J=10.3Hz, 1 H), 2.97 (dd, J=13.9, 2.1 Hz, 1 H), 1.62 (m, 1 H), 1.35 (s, 9H), 1.08 (m, 1H), 0.77 (t, J=5.4Hz, 1 H). ES-LCMS m/z 390.30 (M+Na).
Preparation 11B: 1,1-dimethylethyl [((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate
Figure imgf000065_0001
To a solution of [((1R,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]amine (12.6g, 47.13mmol, 1eq), accessed via the method of 4B, and triethylamine (5.25g, 51.8mmol, 1.1eq) in 200mL DCM cooled to 0°C was added di(terf-butyl) dicarbonate (10.79g, 49.48mmol, 1.05eq). The resultant mixture was stirred 2h at 0°C followed by 16h at ambient temperature. The reaction mixture was diluted with DCM, washed successively with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated to give the title compound (16.6g, 45.17mmol, 96%) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.42-7.14 (m, 10H), 4.50 (m, 1 H), 4.35-4.25 (m, 2H), 3.50-3.45 (m, 1 H), 3.21-3.17 (m, 1 H), 3.10-3.05 (m, 1 H), 3.00-2.95 (m, 1 H), 1.36 (s, 9H), 1.07-1.04 (m, 1 H), 0.82- 0.798(m, 1H). ES-LCMS m/z 368.2 (M+H).
Preparation 12A: 1 ,1-dimethylethyl methyl[((1 S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate
Figure imgf000065_0002
To a solution of 1 ,1-dimethylethyl [((1 S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate (39.2g, 92mmol), accessed via the method of 11 A, and methyl iodide (39.2g, 276mmol, 3eq) in 300mL THF cooled to 0°C was added 1 M sodium bis(trimethylsilyl)amide in THF (138mL, 138mmol, 1.5eq). The reaction mixture was stirred 2h at 0°C followed by 16h at ambient temperature. The reaction mixture was partitioned between EtOAc and water, the phases separated, the aqueous phase extracted twice with EtOAc, the organic phases combined, washed with brine, dried over MgSO , filtered and concentrated to an amber oil. The crude material was purified by flash chromatography (SiO2, eluted successively with DCM/hexanes (1 :1), DCM, and EtOAc/hexanes (1 :4)) to give the title compound (22.25g, 58mmol, 63%) as a pale yellow oil. ES-LCMS m/z 404.30(M+Na).
Preparation 12B: 1 ,1-dimethylethyl methyl[((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate
Figure imgf000066_0001
To a solution of 1 ,1-dimethylethyl [((1R,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cycIopropyl)methyl]carbamate (7.5g, 20.4mmol), accessed via the method of 11B, and methyl iodide (14.4g, 102.0mmol, 5eq) in 100mL THF cooled to 0°C was added 1 M sodium bis(trimethylsilyl)amide in THF (30.6mL, 30.6mmol, 1.5eq). The reaction mixture was stirred 8h at 0°C followed by 16h at ambient temperature. The reaction mixture was partitioned between EtOAc and water, the phases separated, the aqueous phase extracted twice with EtOAc, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to an amber oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (1:4)) to give the title compound (3.1g, 8.1mmol, 40%) as a pale yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.34-7.18 (m, 10H), 4.36-4.27 (m, 2H), 3.67-3.45 (m, 1H), 3.26-3.13 (m, 2H), 3.07-2.99 (m, 1 H), 2.77-2.62 (m, 3H), 1.39-0.80 (m, 12H). ES-LCMS m/z 404.2 (M+Na).
Preparation 13A: 1 ,1-dimethylethyl {[(1S,2R)-2-(hydroxymethyl)-1- phenylcyclopropyljmethyljmethylcarbamate
Figure imgf000066_0002
1 ,1-dimethylethyl methyl[((1S,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate (20.65g, 54mmol), accessed via the method of Preparation 12A, was combined with 10% palladium on activated carbon (2.00g) in 250mL ethyl alcohol and hydrogenated under 1atm H2(g) for 3h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to a yellow oil. The crude material was purified by flash chromatography on silica eluted with 5->25%EtOAc/DCM. Appropriate fractions were combined and concentrated to give the title compound (12.02g, 41.2mmol, 76%) as a colorless oil. 1H NMR (300 MHz, DMSO-d6, 90°C) δ 7.30-7.22 (m, 9H), 7.15 (m, 1H), 4.41 (t, J=5.1Hz, 1H), 3.87 (d, J=14.5Hz, 1H), 3.74 (m, 1H), 3.52 (m, 1 H), 3.31 (d, J=14.4Hz, 1 H), 2.63 (s, 3H), 1.21 (s, 9H), 1.20-1.07 (m, 2H), 0.77 (m, 1 H). ES-LCMS m/z 314.21 (M+Na).
Preparation 13B: 1,1-dimethylethyl {[(1R,2R)-2-(hydroxymethyl)-1- phenylcyclopropyl]methyl}methylcarbamate
Figure imgf000067_0001
1 ,1-dimethylethyl methyl[((1 ,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate (3.1g, 8.1 mmol), accessed via the method of Preparation 12B, was combined with 10% palladium on activated carbon (0.50g) in ethyl alcohol and hydrogenated under 1atm H2(g) for 0.5h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (4:6)) to give the title compound (2.2g, 7.5mmol, 95%) as a pale yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.32-7.20 (m, 5H), 3.70-3.54 (m, 1H), 3.34-3.18 (m, 3H), 2.76-2.60 (m, 3H), 1.41-1.22 (m, 11 H), 1.00 (m, 1 H), 0.87-0.85 (m, 1H). ES-LCMS m/z 314.1 (M+Na).
Preparation 13C: 1 ,1-dimethylethyl {[(1R,2R)-2-(hydroxymethyl)-1- phenylcyclopropyl]methyl}carbamate
Figure imgf000068_0001
1 ,1-dimethylethyl [((1R,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methyl]carbamate (8.0g, 21.7mmoI), accessed via the method of Preparation 11B, was combined with 10% palladium on activated carbon (0.8g) in ethyl alcohol and hydrogenated under 1atm H2(g) for 2.5h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (4:6)) to give the title compound (5.8g, 20.9mmol, 96%) as a pale yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.35-7.25 (m, 5H), 3.52-3.48 (m, 1H), 3.35-3.30 (m, 1 H), 3.23-3.19 (m, 1 H), 3.10-3.07 (m, 1 H), 1.45-1.37 (m, 11 H), 1.04-1.04 (m, 1 H), 0.87-0.84 (m, 1 H). LCMS m/z 300.1 (M+Na).
Preparation 14A: 1 ,1-dimethylethyl {[(1 S,2R)-2-formyl-1 - phenylcyclopropyl]methyl}methylcarbamate
Figure imgf000068_0002
1 ,1-dimethylethyl {[(1S,2R)-2-(hydroxymethyl)-1- phenylcyclopropyl]methyl}methylcarbamate (12.02g, 41.2mmol), accessed via the method of Preparation 13A, was dissolved in 200mL DCM with 6.2mL 2- methylpropan-2-ol and treated with Dess-Martin Periodinane (28.0g, 66.0mmol, 1.6eq) in 200mL DCM at ambient temperature for 3h. The reaction mixture was diluted with 1 L diethyl ether and treated with 400mL 1 N NaOH at ambient temperature for 30min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (1 :4)) to give the title compound (10.7, 36.9mmol, 89%). 1H NMR (400 MHz, CDCI3) δ 9.77-9.65 (m, 1 H), 7.33-7.23 (m, 5H), 3.75-3.63 (m, 2H), 2.72-2.50 (m, 3H), 2.26-2.19 (m, 1H), 1.87-1.81 (m, 1 H), 1.65-1.61 (m, 1 H), 1.31-1.18 (m, 9H). LCMS m/z 312.2 (M+Na).
Preparation 14B: 1 ,1-dimethylethyl {[(1R,2R)-2-formyl-1- phenylcyclopropyl]methyl}methylcarbamate
Figure imgf000069_0001
1 ,1-dimethylethyl {[(1 R,2R)-2-(hydroxymethyl)-1 - phenylcyclopropyl]methyl}methylcarbamate (3.8g, 13.0mmol), accessed via the method of Preparation 13B, was dissolved in 35mL DCM with 1.1mL 2- methylpropan-2-ol and treated with Dess-Martin Periodinane (8.8g, 20.8mmol, 1.6eq) in 35mL DCM at ambient temperature for 2h. The reaction mixture was diluted with 50mL diethyl ether and treated with 50mL 1 N NaOH at ambient temperature for 15min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted EtOAc/hexanes (3:7)) to give the title compound (3.2g, H .Ommol, 84%). 1H NMR (400 MHz, CDCI3) δ 8.49-8.47 (m, 1H), 7.29-7.24 (m, 5H), 3.62-3.58 (m, 1 H), 3.33-3.22 (m, 1 H), 2.72-2.58 (m, 3H), 1.84-1.81 (m, 1 H), 1.71- 1.53 (m, 1H), 1.34-1.25 (m, 10H). ES-LCMS m/z 312.2 (M+Na).
Preparation 14C: 1 ,1-dimethylethyl {[(1R,2R)-2-formyl-1- phenylcyclopropyljmethyljcarbamate
Figure imgf000069_0002
1 ,1-dimethylethyl {[(1R,2R)-2-(hydroxymethyl)-1-phenylcyclopropyl]methyl}carbamate (5.8g, 20.9mmol), accessed via the method of Preparation 13C, was dissolved in 100mL DCM with 3.1 mL 2-methylpropan-2-ol and treated with Dess-Martin Periodinane (14.1g, 33.4mmol, 1.6eq) in 100mL DCM at ambient temperature for 3h. The reaction mixture was diluted with 500mL diethyl ether and treated with 200mL 1 N NaOH at ambient temperature for 15min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO4, filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (1 :4)) to give the title compound (4.2g, 15.2mmol, 73%). 1H NMR (400 MHz, CDCI3) δ 8.51-8.50 (m, 1 H), 7.34-7.24 (m, 5H), 4.55 (m, 1 H), 3.44-3.39 (m, 1H), 3.25-3.20 (m, 1H), 2.13-2.08 (m, 1 H), 1.80-1.78 (m, 1 H), 1.64-1.61 (m, 1 H), 1.37 (s, 9H). ES-LCMS m/z 298.1 (M+Na).
Preparation 14D: 1,1-dimethylethyl {[(1R,2S)-2-formyl-1- phenylcyclopropyljmethyljmethylcarbamate
Figure imgf000070_0001
Starting from phenylacetonitrile and (2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl 4- methylbenzenesulfonate and using the methods of Preparations 1, 2, 3A, 4A, 11 A, 12A, 13A and 14A sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 14E: 1 ,1-dimethylethyl {[(1S,2S)-2-formyl-1- phenylcyclopropyl]methyl}methylcarbamate
Figure imgf000070_0002
Starting from phenylacetonitrile and (2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl 4- methylbenzenesulfonate and using the methods of Preparations 1, 2, 3B, 4B, 11B, 12B, 13B, and 14B sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 14F: 1 ,1-dimethylethyl {[(1S,2S)-2-formyl-1- phenylcyclopropyl]methyl}carbamate
Figure imgf000071_0001
Starting from phenylacetonitrile and (2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl 4- methylbenzenesulfonate and using the methods of Preparations 1 , 2, 3B, 4B, 11 B, 13C, and 14C sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 15: Compounds of generic structure:
Figure imgf000071_0002
In combinatorial fashion, aldehydes prepared by the methods of Preparations 14A-F (0.35mmol) in 3mL DCE were treated with various secondary amines (0.35mmol, 1eq) and mp-sodium triacetoxyborohydride (500mg, 1.04mmol, 3eq) at ambient temperature for 20h with continuous agitation. The reaction mixtures were each filtered. The remaining resin was treated with 4mL DCM with agitation for 1 h and the organics separated via filtration. The organic filtrates were concentrated to dryness and carried forward without purification or characterization. Preparation 16: Compounds of generic structure:
Figure imgf000072_0001
Compounds prepared by the method of Preparation 15 were treated with 1mL trifluoroacetic acid in 2mL DCM and 2mL DCE for 5h at ambient temperature with slight agitation. The reaction mixtures were concentrated and partitioned between DCM (2mL) and saturated NaHCO3 (2mL) and the organic phases separated via filtration through hydrophobic frit tube assemblies. The organic filtrates were concentrated to dryness and carried forward without purification or characterization.
Preparation 17: Compounds of general formula:
Figure imgf000072_0002
The compounds prepared according to the method of Preparation 16 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. The reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF. The resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
Preparation 18: Compounds of general formula:
Figure imgf000073_0001
The compounds prepared according to the method of Preparation 16 were dissolved in 3mL DCE (1:1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE. The resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
The following demonstrate the above-referenced general scheme:
Figure imgf000075_0001
Figure imgf000075_0002
As will be appreciated by those skilled in the art, additional compounds of the present invention may be similarly prepared according to the schemes provided herein. Scheme 3:
Figure imgf000076_0001
Preparation 19B: (1R,2R)-1-phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropanecarbaldehyde
Figure imgf000077_0001
To a solution of 300 mL toluene and (1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile (12.0 g, 45.57 mmol, 1eq), accessed via the method of Preparation 3B, at 0°C was added 59.3 mL 1 M diisobutylaluminum hydride (59.3 mmol, 1.3 eq) in tetrahydrofuran. The mixture was stirred at 0°C for 4 h and then at ambient temperature for 18 h before dilution with 500 mL toluene and 500 mL water. The mixture was stirred for 30 min and then filtered through a pad of celite. The organics were isolated, dried over Na2SO4, filtered and concentrated to give the title compound (7.8 g, 29.3 mmol, 64%) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ 9.39 (s, 1 H), 7.39-7.19 (m, 10 H), 4.33-4.23 (m, 2H), 3.36-3.33 (m, 1H), 3.03-2.98 (m, 1 H), 2.16-2.11(m, 1 H), 1.77-1.73 (m, 1 H), 1.46-1.43 (m, 1H).
Preparation 20B: ((1 R,2R)-1 -phenyl-2-
{[(phenylmethyl)oxy]methyl}cyclopropyl)methanol
Figure imgf000077_0002
Sodium borohydride (1.2 g, 32.2 mmol, 1 eq) was added in one portion to a mixture of (1R,2R)-1-phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropanecarbaldehyde (7.8 g, 29.3 mmol, 1 eq), accessed via the method of Preparation 19B, in 100mL ethyl alcohol at ambient temperature. The reaction was stirred at ambient temperature for 18h, concentrated down and the residue partitioned between ethyl acetate and brine. The organics were dried over Na2SO4, filtered and concentrated to give a yellow oil. The crude material was purified by flash chromatography (SiO2, eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (7.8 g, 29.06 mmol, 99%) as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.15 (m, 10H), 4.61 (t, J=5.7 Hz, 1 H), 4.30-4.17 (m, 2H), 3.53-3.48 (m, 1 H), 3.35-3.31 (m, 1 H), 3.02-2.95 (m, 2H), 1.40-1.33 (m, 1H), 0.96-0.93 (m, 1H), 0.72-0.69 (m, 1H). ES-LCMS m/z 291.2 (M+Na).
Preparation 21 B: [({[(1R,2R)-2-(chloromethyI)-2- phenylcyclopropyl]methyl}oxy)methyl]benzene
Figure imgf000078_0001
A mixture of polymer-bound triphenylphosphine (31.64 g, 67.08 mmol, 3 eq) and carbon tetrachloride (6.5 mL, 67.08 mmol, 3 eq) in 300 mL DCM was stirred at ambient temperature for 30 min. To this was added a solution of ((1R,2R)-1-phenyl- 2-{[(phenylmethyl)oxy]methyl}cyclopropyl)methanol (6.0 g, 22.36 mmol, 1 eq), accessed via the method of Preparation 20B, in 50 mL DCM and the entire reaction mixture was stirred at ambient temperature for 16 h. The mixture was then filtered and the resin washed with excess DCM. The organics were concentrated down to give the title compound (6.4g, 22.36 mmol, 100%) as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.17 (m, 10H), 4.31-4.16 (m, 2H), 4.10-4.07 (m, 1 H), 3.56-3.53 (m, 1H), 3.08-3.04 (m, 1 H), 2.92-2.87 (m, 1 H), 1.63-1.56 (m, 1 H), 1.08-0.99 (m, 2H).
Preparation 22B: ((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)acetonitriIe
Figure imgf000078_0002
A mixture of [({[(1 ,2R)-2-(chloromethyl)-2- phenylcyclopropyl]methyl}oxy)methyl]benzene
[(1R,2R)-2-(chloromethyl)-2-phenylcyclopropyl]methyl phenylmethyl diethyl ether (6.4 g, 22.32 mmol, 1 equiv), accessed via the method of Preparation 21 B, potassium cyanide (2.18 g, 33.47 mmol, 1.5 eq) and potassium carbonate (6.17 g, 44.63 mmol, 2 eq) in 200 mL DMF was heated to 80°C for 18 h. The reaction was then partitioned between ethyl acetate and water. The organics were washed with water (3X) and brine, dried over Na2SO4, filtered and concentrated down. The crude material was purified by flash chromatography (SiO2, eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (5.2 g, 18.13 mmol, 81%) as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 7.39-7.16 (m, 10H), 4.30-4.15 (m, 2H), 3.09-3.01 (m, 2H), 2.88-2.84 (m, 1H), 2.65-2.61 (m, 1 H), 1.51-1.44 (m, 1 H), 1.04-1.00 (m, 1H), 0.94-0.92 (m, 1 H).
Preparation 23B: [2-((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)ethyl]amine
Figure imgf000079_0001
To 18.13 mL 1 M lithium aluminum hydride(18.13 mmol) in diethyl ether at 0°C was added ((1 R,2R)-1 -phenyl-2-{[(phenylmethyl)oxy]methyl}cyclopropyl)acetonitrile (5.2 g, 18.13 mmol), accessed via the method of Preparation 22B, dissolved in 20 mL diethyl ether. After complete addition, the reaction mixture was stirred at 0°C for 3 h. The reaction mixture was diluted with 400 mL diethyl ether and quenched with successive addition of 0.6mL water, 0.6mL 15% NaOH, and 3.0mL water. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated to give the title product (5.1 g, 18.13 mmol 100%) as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 7.29-7.14 (m, 10H), 4.29-4.16 (m, 2H), 3.04-2.99 (m, 1 H), 2.91-2.86 (m, 1 H), 2.39-2.27 (m, 2H), 1.88-1.83 (m, 1H), 1.28-1.19 (m, 2H), 0.84-0.81 (m, 1H), 0.73-0.71 (m, 1H).
Preparation 24B: 1,1-dimethylethyl [2-((1R,2R)-1-phenyl-2- {[(phenyImethyl)oxy]methyl}cyclopropyl)ethyl]carbamate
Figure imgf000079_0002
To a solution of [2-((1R,2R)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)ethyljamine (5.1 g, 18.12 mmol, 1eq), accessed via the method of 23B, and triethylamine (2.78 mL, 19.03 mmol, 1.1 eq) in 75 mL DCM cooled to 0°C was added di(terf-butyl) dicarbonate (4.15 g, 19.03 mmol, 1.05eq). The resultant mixture was stirred 2h at 0°C followed by 16h at ambient temperature. The reaction mixture was diluted with DCM, washed successively with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated down. The crude material was purified by flash chromatography (SiO2, eluted successively with hexanes and EtOAc/hexanes (1 :4)) to give the title product (5.9 g, 15.46 mmol, 85%) as a clear oil. 1H NMR (400 MHz, DMSO-de) δ 7.29-7.17 (m, 10H), 6.60-6.58 (m, 1H), 4.29-4.16 (m, 2H), 3.01-2.97 (m, 1 H), 2.91-2.87 (m, 1 H), 2.83-2.77 (m, 1 H), 2.71-2.66 (m, 1 H), 1.91-1.85 (m, 1 H), 1.33-1.21 (m, 11 H), 0.83-0.80 (m, 1 H), 0.74-0.72 (m, 1 H). ES-LCMS m/z 404.2 (M+Na).
Preparation 26C: 1,1-dimethylethyl {2-[(1R,2R)-2-(hydroxymethyl)-1- phenylcyclopropyl]ethyl}carbamate
Figure imgf000080_0001
1 , 1 -dimethylethyl [2-((1 R,2R)-1 -phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropyl)ethyl]carbamate (5.9 g, 15.46 mmol), accessed via the method of Preparation 24B was combined with 10% palladium on activated carbon (600 mg) in 100 mL ethyl alcohol and hydrogenated under 1atm H2(g) for 3h at ambient temperature. The catalyst was filtered off through celite and the filtrate concentrated to give the title compound (4.1 g, 14.07 mmol, 91 %) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.27-7.12 (m, 5H), 6.59-6.56 (m, 1 H), 4.31-4.29 (m, 1 H), 3.00-2.94 (m, 1 H), 2.87-2.66 (m, 3H), 1.88-1.82 (m, 1 H), 1.32- 1.25 (m, 10H), 1.11-1.05 (m, 1 H), 0.76-0.73 (m, 1 H), 0.65-0.63 (m, 1H). ES-LCMS m/z 314.1 (M+Na).
Preparation 27C: 1,1-dimethylethyl {2-[(1R,2R)-2-formyl-1- phenylcyclopropyljethyljcarbamate
Figure imgf000081_0001
1 ,1-dimethylethyl {2-[(1R,2R)-2-(hydroxymethyl)-1- phenylcyclopropyl]ethyl}carbamate (4.1 g, 14.07 mmol), accessed via the method of Preparation 26C, was dissolved in 40 mL DCM with 1.2 mL 2-methylpropan-2-ol and treated with Dess-Martin Periodinane (9.55 g, 22.51 mmol, 1.6eq) in 40 mL DCM at ambient temperature for 3h. The reaction mixture was diluted with 50 mL diethyl ether and treated with 50 mL 1 N NaOH at ambient temperature for 30min. The organic phase was separated, the aqueous phase extracted twice with diethyl ether, the organic phases combined, washed with brine, dried over MgSO , filtered and concentrated to a colorless oil. The crude material was purified by flash chromatography (SiO2, eluted with EtOAc/hexanes (3:7)) to give the title compound (3.5 g, 12.10 mmol, 86%). 1H NMR (400 MHz, CDCI3) δ 8.43-8.41 (m, 1H), 7.31-7.20 (m, 5H), 4.41 (m, 1 H), 3.04-2.95 (m, 2H), 2.16-2.10 (m, 1 H), 1.99-1.94 (m, 1 H), 1.88- 1.85 (m, 1 H), 1.54-1.46 (m, 1 H), 1.38 (s, 10 H). LCMS m/z 312.2 (M+Na).
Preparation 27F: 1 ,1-dimethylethyl {2-[(1 S,2S)-2-formyl-1- phenylcyclopropyl]ethyl}carbamate
Figure imgf000081_0002
Starting from (1S,2S)-1-phenyl-2- {[(phenylmethyl)oxy]methyl}cyclopropanecarbonitrile, accessed via the method of 3B, and using the methods of Preparations 19B, 20B, 21 B, 22B, 23B, 24B, 26C, and 27C sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations. Preparation 28: Compounds of generic structure:
Figure imgf000082_0001
In combinatorial fashion, aldehydes prepared by the methods of Preparations 27A-F (0.35mmol) in 3mL DCE were treated with various secondary amines (0.35mmol, 1eq) and mp-sodium triacetoxyborohydride (500mg, 1.04mmol, 3eq) at ambient temperature for 20h with continuous agitation. The reaction mixtures were each filtered. The remaining resin was treated with 4mL DCM with agitation for 1h and the organics separated via filtration. The organic filtrates were concentrated to dryness and carried forward without purification or characterization.
Preparation 29: Compounds of generic structure:
Figure imgf000082_0002
Compounds prepared by the method of Preparation 28 were treated with 1 mL trifluoroacetic acid in 2mL DCM and 2mL DCE for 5h at ambient temperature with slight agitation. The reaction mixtures were concentrated and partitioned between DCM (2mL) and saturated NaHCO3 (2mL) and the organic phases separated via filtration through hydrophobic frit tube assemblies. The organic filtrates were concentrated to dryness and carried forward without purification or characterization. Preparation 30: Compounds of general formula:
Figure imgf000083_0001
The compounds prepared according to the method of Preparation 29 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. The reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF. The resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C185 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved. Preparation 31 : Compounds of general formula:
Figure imgf000084_0001
The compounds prepared according to the method of Preparation 29 were dissolved in 3mL DCE (1:1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE. The resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral
HPLC was performed on representative samples to confirm that homochiral integrity had been preserved. Scheme 4:
Figure imgf000085_0001
Preparation 32: (4S)-2-(3-chlorophenyl)-4-hydroxy-6-[(phenylmethyl)oxy]hexanenitrile
Figure imgf000085_0002
(3-Chlorophenyl)acetonitrile (8.62 mL, 72.9 mmol) in 100ml of THF was cooled to - 78°C. Butyllithium (35.1 mL, 56.1 mmol, 1.6 M in THF) was added over 20 minutes and stirred for an additional 15 min at -78°C. (2R)-2-{2-
[(phenylmethyl)oxy]ethyl}oxirane (10.0 g, 56.1 mmol, Synthesis 1992, 7 , 621-623) in 20 mL of THF was added over 30 minutes and stirred for an additional hour at -78°C. After warming to room temperature the solvent was evaporated and the orange red oil was chromatographed on silica gel with 20-25% EtOAc in Hexanes to give the title compound (11.05g, 58%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.8 (m, 3 H) 3.6 (m, 1 H) 3.7 (m. 2 H) 4.1 (m, 2 H) 4.5 (m, 2 H) 7.3 (m, 9 H).
Preparation 33: (1 S)-3-(3-chlorophenyl)-3-cyano-1-{2- [(phenylmethyl)oxy]ethyl}propyl 4-methylbenzenesulfonate
Figure imgf000086_0001
To a solution of (4S)-2-(3-chlorophenyl)-4-hydroxy-6-[(phenylmethyl)oxy]hexanenitrile (6.00 g, 18.2 mmol) in 50% CHCI3 in pyridine at 0°C was added DMAP (2.22 g) and toluenesulfonyl chloride (10.4 g, 54.5 mmol). After warming to room temperature over several hours, the reaction mixture was stored in the freezer for 2 days. After an aqueous work up with 1 N HCI the organic layer was dried over MgSO4 and evaporated to an oil. Chromatography on silica with 25% EtOAc in Hexanes afforded the title compound (5.68 g, 66%) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.9 (m, 2 H) 2.1 (m, 2 H) 2.3 (m, 2 H) 2.4 (s, 3 H) 3.4 (m, 1 H) 3.5 (m, 1 H) 4.4 (m, 2 H) 7.1 (m, 1 H) 7.3 (m, 10 H) 7.8 (m, 2 H)
Preparation 34: (1R,2R)-1-(3-chlorophenyl)-2-{2- [(phenylmethyl)oxy]ethyl}cyclopropanecarbonitrile
Figure imgf000086_0002
3.2 mL 1 M LHMDS in hexanes (3.2 mmol) was added to 15 mL of DMF and cooled to -40°C. To this was added a solution of (1S)-3-(3-chlorophenyl)-3-cyano-1-{2- [(phenylmethyI)oxy]ethyl}propyl 4-methylbenzenesulfonate (1.00 g, 2.12 mmol) in 5 mL of DMF over 10 minutes and stirred for 40 minutes After warming to room temperature the reaction was stirred until no starting material remained by TLC. The reaction mixture was poured into 100 mL water, extracted with 50mL EtOAc, the organic phase isolated, washed with brine and dried over MgSO4. The resulting residue was purified by silica gel chromatography with 25% EtOAc in hexanes to give the title compound (436 mg, 65% yield). 1 H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.4 (dd, J=7.5, 5.6 Hz, 1 H) 1.5 (m, 1 H) 1.7 (m, 1 H) 2.0 (m, 2 H) 3.6 (m, 2 H) 4.5 (d, J=2.2 Hz, 2 H) 7.1 (m, 1 H) 7.2 (m, 3 H) 7.3 (m, 5 H).
Preparation 35: [((1R,2R)-1-(3-chlorophenyl)-2-{2- [(phenylmethyl)oxy]ethyl}cyclopropyl)methyl]amine
Figure imgf000087_0001
A solution of (1 R,2R)-1 -(3-chlorophenyl)-2-{2-
[(phenylmethyl)oxy]ethyl}cyclopropanecarbonitrile (1.26 g, 4.0 mmol) in diethyl ether at 0°C was treated with 2 equivalents of LAH (1 M in diethyl ether). After 1.5 hours at 0°C, water was added dropwise until no further evolution of gas was observed. The aluminum salts were filtered off and washed with diethyl ether. Evaporation of the diethyl ether afforded the title compound. 1 H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.5 (dd, J=5.9, 4.8 Hz, 1 H) 1.0 (dd, J=8.9, 4.7 Hz, 1 H) 1.2 (m, 1 H) 1.4 (s, 2 H) 1.8 (m, 2 H) 2.9 (m, 2 H) 3.6 (m, 2 H) 4.6 (s, 2 H) 7.2 (m, 3 H) 7.3 (m, 2 H) 7.4 (m, 4 H) .
Preparation 36: 1 ,1-dimethylethyl [((1 ,2R)-1-(3-chlorophenyl)-2-{2- [(phenyImethyl)oxy]ethyl}cyclopropyl)methyl]methylcarbamate
Figure imgf000087_0002
A solution of [((1R,2R)-1-(3-chlorophenyl)-2-{2- [(phenylmethyl)oxy]ethyl}cyclopropyl)methyl]amine (1.67 g, 5.29 mmol) and triethylamine (0.74 mL, 5.29 mmol) in DCM was cooled to 0°C. Di-ferf-butyl dicarbonate (1.15 g, 5.29 mmol) was added as a solid and stirred at 0°C for 1 hour. The reaction mixture was evaporated to give 2.27 g of an oil which was redissolved in THF and iodomethane (2.27 g, 15.98 mmol) and cooled to 0 C°. NaHMDS (8.0 mL, 1 M in THF) was added over 20 minutes to the stirring solution. After warming to room temperature the reaction was poured into water and diethyl ether. The diethyl ether was isolated, washed with water, dried over MgSO4 and evaporated to afford the title compound (2.08 g, 91% yield). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.7 (m, 1 H) 1.2 (m, 9 H) 1.3 (m, 3 H) 1.7 (m, 1 H) 1.9 (m, 1 H) 2.6 (s, 1 H) 2.8 (s, 2 H) 3.6 (m, 2 H) 3.9 (d, J=14.8 Hz, 1 H) 4.6 (s, 2 H) 7.2 (m, 3 H) 7.3 (m, 2 H) 7.3 (m, 4 H)
Preparation 37A: 1 ,1-dimethylethyl {[(1 ,2R)-1-(3-chlorophenyl)-2-(2- oxoethyl)cyclopropyl]methyl}methylcarbamate
Figure imgf000088_0001
A solution of 1 ,1-dimethylethyl [((1R,2R)-1-(3-chlorophenyl)-2-{2- [(phenylmethyl)oxy]ethyl}cyclopropyl)methyl]methylcarbamate (2.08 g, 4.83mmole) in 50 mL EtOAc was stirred overnight under 1 atmosphere of H2 with 360 mg of 10% Pd on carbon. The suspension was filtered through celite and evaporated to afford 1.84 g of an oil. The oil was dissolved in DCM and added to a solution of Dess-Martin periodinane (3.67 g, 8.66 mmol) and 2-methyl-2-propanol (828 μl, 8.66mmole) in DCM. After stirring overnight, the reaction mixture was mixed with 100 mL of 1N NaOH and 5.0 g of Na2SO4 for 20 minutes. 100 mL of diethyl ether was added and the organic layer washed with 1 N NaOH, water and dried over MgSO4. Removal of solvent afforded the title compound as a crude oil which was used without further purification. ES-LCMS m/z 360 (M+Na).
Preparation 37B: terf-butyl {[(1R,2S)-1-(3-chlorophenyl)-2-(2- oxoethyl)cyclopropyl]methyl}methylcarbamate
Figure imgf000089_0001
Starting from (3-chlorophenyl)acetonitrile and (2S)-2-{2-
[(phenylmethyl)oxy]ethyl}oxirane and using the methods of Preparations 32, 33, 34, 35, 36, and 37A sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
Preparation 38: Compounds of generic structure:
Figure imgf000089_0002
In combinatorial fashion, aldehydes prepared by the method of Preparations 37A-B (0.35mmol) in 3mL DCE were treated with various secondary amines (0.35mmol, 1eq) and mp-sodium triacetoxyborohydride (500mg, 1.04mmol, 3eq) at ambient temperature for 20h with continuous agitation. The reaction mixtures were each filtered. The remaining resin was treated with 4mL DCM with agitation for 1h and the organics separated via filtration. The organic filtrates were concentrated to dryness and carried forward without purification or characterization.
Preparation 39: Compounds of generic structure:
Figure imgf000089_0003
Compounds prepared by the method of Preparation 38 were treated with 1 mL trifluoroacetic acid in 2mL DCM and 2mL DCE for 5h at ambient temperature with slight agitation. The reaction mixtures were concentrated and partitioned between DCM (2mL) and saturated NaHCO3 (2mL) and the organic phases separated via filtration through hydrophobic frit tube assemblies. The organic filtrates were concentrated to dryness and carried forward without purification or characterization.
Preparation 40: Compounds of general formula:
Figure imgf000090_0001
The compounds prepared according to the method of Preparation 39 were dissolved in 3mL DCE and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. The reaction plates were concentrated down and the residues taken up in 1mL DMF for reaction. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by an acid (0.13mmol, 1.1 eq) in 0.5mL DMF and HATU (0.12mmol, 1eq) in 0.5 mL DMF. The resultant reaction mixtures were agitated at ambient temperature for 18h and HATU byproducts scavanged by addition of polymer-bound carbonate (0.36mmol, 3eq) and agitation at ambient temperature for 3h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral HPLC was performed on representative samples to confirm that homochiral integrity had been preserved. Preparation 41 : Compounds of general formula:
Figure imgf000091_0001
The compounds prepared according to the method of Preparation 39 were dissolved in 3mL DCE (1 :1) and further split out in combinatorial fashion such that each reaction was performed on a theoretical scale of 0.12mmol in 1mL DCE. Polymer- bound diisopropylamine (0.48mmol, 4eq) was added to each well followed by either an acid chloride or sulfonyl chloride (0.12mol, 1eq) in 1mL DCE. The resultant reaction mixtures were agitated at ambient temperature for 16h and excess acid or sulfonyl chloride scavanged by addition of polymer-bound trisamine (0.36mmol, 3eq) and agitation at ambient temperature for 4h. The reaction plates were filtered and the filtrates concentrated to dryness. Crude products were dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. Chiral
HPLC was performed on representative samples to confirm that homochiral integrity had been preserved.
The following example demonstrates the above-referenced general scheme:
Example 12: Λ/-[((1 S,2S)-1 -(3-chlorophenyl)-2-{2-[1 -(3-methylphenyl)-4-oxo-1 ,3,8- triazaspiro[4.5]dec-8-yl]ethyl}cyclopropyl)methyl]-Λ/-methylcyclopentanecarboxamide
Figure imgf000092_0001
The title compound was prepared according to the methods of Preparation 41. ES- LCMS m/z 661.36 (M+H).
Scheme 5:
Figure imgf000092_0002
Figure imgf000092_0003
Preparation 42: Ethyl (1S,2R)-2-{[(3-endo)-3-(2-methyl-1H-benzimidazol-1-yl)-8- azabicyclo[3.2.1]oct-8-yl]methyl}-1-phenylcyclopropanecarboxylate
Figure imgf000092_0004
Ethyl (1S,2R)-2-(bromomethyl)-1-phenylcyclopropanecarboxylate (538mg, 1.90mmol, 1eq., J. Med. Chem. 1987, 30(2), 318-325) was combined with 1 -[(3-endo)-8- azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole (700mg, 1.90mmol, 1eq., WO 00/38680), potassium carbonate (790mg, 5.70mmol, 3eq.) and a catalytic amount of potassium iodide in 10mL DMF and stirred 16h at 85°C. The reaction mixture was partitioned between EtOAc and water (pH = 9) and the organic phase isolated. The organic phase was combined with fresh water and the pH adjusted to 2 with 1 N HCI. The aqueous phase was isolated, the pH adjusted to 11 with 1 N NaOH, and extracted with DCM. The organic phase was isolated, dried over MgSO4, filtered and concentrated to give the title compound (574mg, 1.29mmol, 68%) as a brown foam. 1 H NMR (400 MHz, DMSO-D6, 85°C) δ ppm 1.2 (t, J=7.1 Hz, 3 H) 1.4 (dd, J=9.0, 4.5 Hz, 1 H) 1.6 (dd, J=7.1 , 4.5 Hz, 1 H) 1.8 (m, 3 H) 1.9 (m, 2 H) 2.1 (m, 2 H)
2.4 (m, 2 H) 2.5 (s, 3 H) 2.7 (m, 1 H) 3.4 (m, 1 H) 3.7 (m, 1 H) 4.1 (q, J=7.1 Hz, 2 H) 4.8 (m, 1 H) 7.1 (m, 2 H) 7.2 (m, 1 H) 7.3 (t, J=7.4 Hz, 2 H) 7.4 (m, 2 H) 7.4 (m, 1 H)
7.5 (m, 1 H). ES-LCMS m/z 444.24 (M+H).
Preparation 43: (1S,2R)-2-{[(3-et7cfo)-3-(2-methyl-1H-benzimidazol-1-yl)-8- azabicyclo[3.2.1]oct-8-yl]methyl}-1 -phenylcyclopropanecarboxylic acid
Figure imgf000093_0001
Ethyl (1 S,2R)-2-{[(3-er?ofo)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8-azabicyclo[3.2.1 joct- 8-yl]methyl}-1-phenylcyclopropanecarboxylate (574mg, 1.29mmol, 1eq.) was dissolved in 1.9mL ethyl alcohol and treated with 1.9mL 1 N LiOH (1.9mmol, 1.5eq.) 16h at ambient temperature. The reaction mixture was concentrated to dryness, chased three times with toluene and pumped on under high vacuum to dryness. The crude product was triturated with DCM which was decanted off leaving the title compound (526mg, 1.27mmol, 99%) as a white solid residue. 1 H NMR (400 MHz, DMSO-D6, 85°C) δ ppm 1.3 (dd, J=8.9, 4.4 Hz, 1 H) 1.5 (dd, J=7.0, 4.4 Hz, 1 H) 1.7 (m, 3 H) 1.9 (m, 2 H) 2.2 (m, 2 H) 2.5 (m, 2 H) 2.5 (s, 3 H) 2.7 (dd, J=12.8, 5.4 Hz, 1 H) 3.4 (m, 1 H) 3.7 (m, 1 H) 4.9 (m, 1 H) 7.1 (m, 2 H) 7.2 (m, 1 H) 7.3 (m, 2 H) 7.4 (m, 2 H) 7.4 (m, 1 H) 7.5 (m, 1 H). ES-LCMS m/z 416.19 (M+H).
Preparation 44: ((1S,2S)-2-{[(3-encfo)-3-(2-methyl-1H-benzimidazol-1-yl)-8- azabicyclo[3.2.1]oct-8-yl]methyl}-1-phenylcyclopropyl)amine
Figure imgf000094_0001
(1 S,2R)-2-{[(3-e/ι cfo)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8-azabicyclo[3.2.1 ]oct-8- yl]methyl}-1-phenylcyclopropanecarboxylic acid (174mg, 0.42mmol, 1eq.) was treated with 10mL thionyl chloride for 16h at ambient temperature. The reaction mixture was concentrated to dryness, chased two times with toluene and pumped dry to give the acid chloride as a yellow foam. The acid chloride thus obtained was suspended in 5mL acetone and treated with sodium azide (73mg, 1.12mmol, 2.7eq.) dissolved in 2mL water at ambient temperature. The reaction mixture was stirred 1 h at ambient temperature and then diluted with saturated NaHCO3 and extracted with toluene. The toluene layer was isolated, dried over MgSO4, filtered, and the filtrate heated at 90°C for 2h. After cooling, water was added to the reaction mixture and the pH adjusted to 2 with 1 N HCI. The aqueous phase was isolated, the pH adjusted to 10 with 1N NaOH, extracted two times EtOAc, the organic phases combined, dried over MgSO4, filtered and concentrated to give the title compound (61mg, 0.16mmol, 38%) as a yellow film. 1 H NMR (400 MHz, DMSO-D6, 85°C) δ ppm 0.7 (m, 1 H) 1.2 (m, 2 H) 1.7 (m, J=7.6 Hz, 2 H) 1.9 (m, 2 H) 2.2 (m, 2 H) 2.4 (m, J=8.6 Hz, 2 H) 2.5 (m, 3 H) 2.6 (m, 2 H) 3.5 (m, 1 H) 3.6 (m, 1 H) 4.7 (m, 1 H) 7.1 (m, 3 H) 7.3 (t, J=7.8 Hz, 2 H) 7.4 (m, 2 H) 7.4 (d, J=7.4 Hz, 1 H) 7.5 (d, J=8.3 Hz, 1 H). ES-LCMS m/z 387.28 (M+H).
Preparation 46, Example 13: Λ/-((1S,2S)-2-{[(3-enc/o)-3-(2-methyl-1H-benzimidazol- 1-yl)-8-azabicyclo[3.2.1]oct-8-yl]methyl}-1-phenylcyclopropyl)benzenesuIfonamide
Figure imgf000094_0002
((1 S,2S)-2-{[(3-et7f- o)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8-azabicyclo[3.2.1 ]oct-8- yl]methyl}-1-phenylcyclopropyl)amine (40mg, 0.103mmol, 1eq.) was dissolved in 2mL DCM/DCE (1 :1 ) and treated with benzenesulfonyl chloride (40uL, 0.310mmol, 3eq.) in the presence of PS-DIEA (40mg, 0.155mmol, 1.5eq) at ambient temperature for 3h. The resin was filtered off and the filtrate concentrated to dryness. The crude product was purified by HPLC on a C-18 column eluted with 0- 100%CH3CN in water buffered with 0.1% TEA. The appropriate fraction was isolated and concentrated to give the title compound (20mg, 0.038mmol, 37%) as a white solid. 1 H NMR (400 MHz, DMSO-D6, 85°C) δ ppm 1.2 (m, 2 H) 1.5 (m, 1 H) 1.7 (m, 2 H) 1.9 (m, 2 H) 2.0 (m, 2 H) 2.2 (dd, .7=12.9, 6.5 Hz, 1 H) 2.4 (m, 2 H) 2.5 (s, 3 H) 2.6 (dd, J=12.5, 5.0 Hz, 1 H) 3.4 (m, 1 H) 3.5 (m, 1 H) 4.7 (m, 1 H) 7.1 (m, 5 H) 7.2 (m, 2 H) 7.4 (m, 3 H) 7.5 (m, 2 H) 7.6 (m, 2 H) 8.4 (s, 1 H). ES-LCMS m/z 527.27 (M+H).
Example 14: Λ/-((1R,2R)-2-{[(3-e/7Qfo)-3-(2-methyl-1 H-benzimidazol-1 -yl)-8- azabicyclo[3.2.1 ]oct-8-yl]methyl}-1 -phenylcyclopropyl)benzenesulfonamide
Figure imgf000095_0001
Starting from ethyl (1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylate (J. Med. Chem. 1987, 30(2), 318-325) and using the methods of Preparations 42, 43, 44 and 46 sequentially, the title product can be obtained in comparable yields and analytical characterization to those obtained in those preparations.
List of abreviations:
LAH = lithium aluminum hydride DCE = dichloroethane
TFA = trifluoroacetic acid
LDA = lithium diisopropylamide
TEA = triethylamine
THF = tetrahydrofuran DCM = dichloromethane
TLC = thin layer chromatography
LHMDS = lithium bis(trimethylsilyl)amide
NaHMDS = sodium bis(trimethylsily!)amide
PS-DIEA = polystyrene supported diisopropylethylamine PS-Trisamine = polystyrene supported trisamine HATU = O-(7-azabenzotriazol-1-yl)-Λ/,Λ,Λ/',Λ/-tetramethyluronium hexafluorophosphate DMF = Λ/,/V-Dimethylformamide DMSO = Dimethyl sulfoxide
DIEA = Λ/,Λ/-Diisopropylethylamine THF = Tetrahydrofuran NaBH(OAc)3 = sodium triacetoxyborohydride EtOAc = ethyl acetate DMAP = dimethylaminopyridine h = hours
HPLC = high performance liquid chromatography SiO2 = silica gel
As will be appreciated by those skilled in the art, additional compounds of the present invention may be similarly prepared according to the schemes provided herein.
BIOLOGICAL DATA The following definitions apply:
IC 50 Concentration of compound that displaces 50% of radioligand plC 50 The determined IC50 value expressed as -log10(IC50)
CC-Chemokine Receptor-5 Binding by Scintillation Proximity Assay (CCR5 SPA) Scintillation Proximity Assay for the Human CC-Chemokine Receptor, CCR-5
This protocol describes a high-throughput screen using SPA binding to identify compounds that inhibit binding of 125l-MIP1α to the human CCR5 chemokine receptor.
CCR5 is a G protein-coupled receptor that binds the natural chemokine ligands,
MIP1 , MIP1β and RANTES. CCR5 acts as a co-receptor with CD4 for entry of HIV- 1 into human T-cells and monocytes. Chemokines also play a role in acute and chronic inflammatory processes. Chemokines are soluble proteins produced and released by a wide variety of cell types during the initial phase of a host response to a forgein substance entering the body.
Human CCR5 receptors were expressed in Chinese Hamster Ovary (CHO) cells, registration # 12025. Cells were grown in suspension and a 50 to 80 ml CCR5 cell pellet was prepared. Membrane preparation: 1) Weigh pellet; 2)Prepare an ice-cold 50mM HEPES buffer, containing 0.0025mg/ml Pefabloc, 0.0001 mg/ml Pepstatin A, 0.0001 mg/ml Leupeptin, 0.0001 mg/ml Aprotinin (protease inhibitor cocktail), pH 7.4; 3) Homogenize pellet in 5 volumes of HEPES buffer; 4) Homogenize again with a glass homogenizer 10 to 20 strokes; 5) Centrifuge homogenate at 18,000 rpm in a F28/36 rotor using a Sorvall RC26 PIUS refrigerated Centrifuge for 30 minutes; 6) Discard supernatant and resuspend pellet in 3 volumes of HEPES buffer; 7) Homogenize and centrifuge again using steps 4-6, 2 more times; 8) Reweigh pellet and homogenize in 3X weight-to-volume of HEPES buffer; 9) Aliquot 0.5 to 1.5ml of the membrane preparation into small vials and store at -80 degrees Centigrade; 10) Determine the protein concentration of the membrane preparation using the Bio-Rad or BCA method; 11) The membrane homogenate will need to be characterized for the assay conditions a.) Protein concentration; b.) Optimal protein-to-bead ratio in SPA; and c.) Saturation curve to determine Kd and Bmax in SPA
The saturation curve binding experiment is performed by adding varying amounts of [125l]MIP1α (0-8.5nM to membranes and beads in concentrations chosen from the optimal protein/bead ratio. The data is analyzed using a non-linear curve-fitting program. The Kd and Bmax are derived from the curve.
Bacitracin 50mg/ml is dissolved in deionized water, brought to a boil for 5 minutes (to destroy protease activity) and cooled. Prepared 1ml aliquots and store at -80°C.
Protease inhibitor cocktail is prepared by dissolving 25 mg/ml of Pefabloc, 1 mg/ml of Leupeptin, 1 mg/ml of Aprotinin and 1 mg/ml of Pepstatin A in 100% DMSO. The cocktail can be aliquoted and stored frozen at -20°C until needed.
Sigmacote: Any reagent bottles and reservoirs that come in contact with the radioligand are treated with Sigmacote to reduce sticking. Rinse containers with undiluted Sigmacote; rinse with deionized water several times, and allow to air dry before using.
Color Quench Assay- [125l] SPA PVT color quench kit, Cat. No. RPAQ 4030, Amersham Ltd. A color quench curve is generated for each Packard TopCount and is stored in each counting protocol specific for the assay. This is done to prevent colored compounds from quenching the scintillation counts.
Compounds Preparation: Compounds for a single concentration determination (One Shots) are delivered in 96 well Packard Optiplates containing 1 μl of compound in 100% DMSO in columns A1- H10 (80 compounds/plate). Column A11 to H11 is used for total binding (Bo) (vehicle-5 μl of the appropriate DMSO concentration) and column A12 to D12 is used for determination of nonspecific binding. No further preparation is required.
Compounds for concentration-response curves (10 points) are delivered in 96- Packard Optiplates containing 1 μl of compound in 100% DMSO in columns A1-H10. A 10-point concentration-response curve is desired for each compound with a starting high concentration of 30 μM (in the assauy final). Column A11 to H11 is used for total binding (Bo) (vehicle-5 μl of the appropriate DMSO concentration) and column A12 to D12 is used for determination of nonspecific binding. No further preparation is required
Materials: 1 M HEPES, pH 7.4, Gibco, Cat. No. 15360-080
Bacitracin, Sigma Catalog. Number. B-0125
Bovine Serum Albumin, Sigma, Cat. No. A-7888
MgCI2, J.T. Baker 2444-01
CaCI2, Sigma, Cat. No. C5080 MIP1α, Peprotech, Cat. No. 300-08
Sigmacote, Sigma, Cat. No. SL2
Scintillation Proximity Beads, Wheat Germ Agglutinin, Amersham, Cat No. RPNQ
0001
[125l]MIP1α, NEN (#NEX298) Packard 96 well flat-bottom Optiplate, Cat. No. 6005190 Falcon 96 well round-bottom plate, Cat. No. 3077 TOPSEAL-S, Packard, Cat. No. 6005161 Dimethyl Sulfoxide, EM Science, Cat. No. MX1458-6 Siliconized Pipette tips, Accutip, volume 200-1300uL, Cat. No. P5048-85 Siliconized Pipette tips, Bio Plas, Inc., volume 1-200uL, Cat. No. 60828-908 Reagent Reservoir, Elkay, Cat. No. 175-RBAS-000
Assay Buffer Preparation:
50 mM HEPES buffer pH 7.4, 1mM CaCI2, 5mM MgCI2(this can be made ahead as a 100X stock), 1% BSA, 0.5 mg/ml Bacitracin, Protease inhibitor Cocktail (see preparation above) 100 uL/100 ml, DMSO is added to equal a final concentration of 2% per well (includes compound %DMSO) if needed.
Experimental Details: r1 5llMIP1α preparation:
Prepared radioligand dilutions in container treated with Sigmacote Reconstitute each 50 μCi vial with 0.5 ml of deionized water and store at 4°C. Specific Activity = 2,000 Ci/mmol Add -60,000 cpm (0.17 nM) to each assay well in 50uL
Bo:
Make a 20% DMSO solution and add 5uls of this to each well in col A11 -H11. This gives a final 2% DMSO concentration for the well when added to the 1% in the assay buffer.
NSB:
Make a stock dilution of MIP1α at 100uM using deionized water; aliquot and freeze. Dilute the MIP-1α stock solution to a concentration of 2 μM in the same 20% DMSO solution used above and add 5 μl to the wells in column A12 to D12 to give a final assay concentration of 100nM. Prepare this in a Sigmacote-treated container
Membrane and SPA Bead preparation-
The final assay concentration for the membrane is 15 μg per well. SPA beads are prepared by adding 5 ml of assay buffer to a 500 mg vial. The final concentration of SPA beads in the assay is 0.25 mg/well. Membranes and beads are premixed as a 1 :1 (membrane: bead) mixture and maintained at mixture at 4°C with constant stirring. 50 μl of the mixture is added to each assay well. After all reagents have been added to the plates (total assay volume 100 μl), shake plates for 4 hours at room temperature. After 4 hours, place the plates on the TopCount in a count the plates on the TopCount for 30 sec per well using an appropriate program (i.e., one with a quench curve established for the conditions of the assay.
Data Reduction:
Data reduction is performed using the Microsoft Excel Addins Robofit or Robosage.
For single concentration assays (One Shots), the result of each test well is expressed as % inhibition using the following formula: 100*(1-(U1-C2)/(C1-C2)). Where U1 is the unknown sample in cpm observed in a particular well, C1 is the average of column 12 cpm observed in the absence of any added inhibitor, and C2 is the average of column 11 cpm observed in the presence of 1 μM of MIP1α.
For concentration-response assays, the result of each test well is expressed as %B/Bo (% total specific binding) using the following formula: 100* (U1-C2)/C1-C2). Curves were generated by plotting the %B/Bo versus the concentration and the IC50 is derived using the equation y=Vmax*(1-(xΛn/(kΛn+xΛn))).
Controls and Standards:
Each plate contains 12 wells of total binding (column A11-H11). The cpm/well are averaged and are used in data reduction as value d .Each plate also contains 4 wells of non-specific binding (wells A12-D12). The counts of these wells are averaged and used in data reduction as value C2.
A standards plate is included in each experiment. This plate contains a 14-point concentration-response curve (in triplicate) for the standard compound MIP1α at a starting concentration of 1 μM. The average historical pKj obtained with MIP1α is 7.6.
The relevant biological response field for a single concentration (One Shots) is % inhibition. Inhibition values of >40 or >50% were considered positive responses. HOS Assay (Also referred to as HOS-LTR-Luciferase Assay)
Materials
DMEM (GibcoBRL # 10564-011) Trpsin-EDTA (GibcoBRL #25300-054)
Heat inactivated Fetal Bovine Serum (FBS) (Hyclone # SH30070.03) 96-well, black-walled, clear-bottom, tissue culture-treated plates (Costar # 3904) 96-well, clear-walled, clear-bottom tissue culture-treated plates (Costar # 3598) Phosphate Buffered Saline (PBS) (GibcoBRL #14190-144) Dimethyl Sulfoxide (DMSO) (Sigma # D2650)
Luclite Luciferase Reporter assay (Packard #6016911) HOS-CD4.CCR5-LTR-Luciferase (Bioresource Registration # 21164): Human Osteosarcoma cell line engineered to overexpress human CD4 and human CCR5 (AIDS Repository cat# 3318) stabily transfected with HIV-1-LTR-Luciferase reporter.
Advanced Preparation
Growth and Maintenance of the HOS-CD4.CCR5-LTR-Luciferase cell line:
The cells were propagated in DMEM containing 2% FBS. Cells were split by standard trypsinization when confluency reached 80% (roughly every 2 to 3 days).
Titering of virus stocks:
HIV-1 virus stocks were titered in the assay system in order to obtain an estimate of the number of infectious particles per unit volume (described as RLU/ml). Virus stocks were diluted into DMEM containing 2% FBS and assayed as described in the "procedure" section below.
Procedure
Black-walled 96-well tissue culture plates were seeded with HOS-CD4.CCR5-LTR- Luciferase @ 0.6 to 1.2 x 103 cells per well in 50ul DMEM containing 2% FBS and placed in a humidified incubator @ 37°C, 5% CO2 overnight. The following day, test compounds were titrated 4-fold at 2X the final concentration in DMEM + 2% FBS + 0.2% DMSO. 50μl of titrated compound was transferred to the HOS cells and the plates were placed in a humidified incubator at 37°C, 5% CO2for 1hr. An additional 60ul of 2X titrated compound was transferred to a clear-walled 96-well tissue culture plate and 60ul of HIV (diluted to appropriate m.o.i.) was added to each well and thoroughly mixed. 100ul of the HIV/compound mixture was transferred to the black- walled plates containing 100ul of cells/compound. The plates were placed in a humidified incubator at 37°C, 5% CO2for 72hr. Following the 72 hour incubation, 150ul of supernatant was removed and 50ul of reconstituted LUCLITE (kit reagent) was added to each well. Each plate was sealed and read in a Topcount (Packard) luminometer at 1s/well.
Data Reduction
Relative Light Units (RLU) were expressed as % control (RLU at drug [ ] / RLU no drug)*100 = % Control IC50 values were determined by any one of the following four nonlinear regression models: y=Vmax*(1 -(xΛn/(KΛn+xΛn)))+Y2 y=Vmax*(1 -(xΛn/(KΛn+xΛn))) y=Vmax*(1-(x/(K+x)))+Y2 y=Vmax*(1-(x/(K+x)))
Where: K is IC50, Y2 is baseline, and N is Hill Coefficient
Each of the compounds of the present invention provides a plC50 value of at least 5 when tested in each of the above-described assays.
Test compounds are employed in free or salt form.
All research complied with the principles of laboratory animal care (NIH publication No. 85-23, revised 1985) and pharmaceutical industry policy on animal use.
Although specific embodiments of the present invention have been illustrated and described in detail, the invention is not limited thereto. The above detailed description of preferred embodiments is provided for example only and should not be construed as constituting any limitation of the invention. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the invention are intended to be included within the scope of the appended claims.

Claims

What is claimed is:
1. A compound of formula (I):
Figure imgf000103_0001
or a pharmaceutically acceptable salt, solvate, or derivative thereof, wherein:
X is a C-i-5 alkylene chain, wherein said X is optionally substituted by one or more =O, =S, -S(O)r, alkyl, or halogen and wherein said Ci-5 alkylene chain may optionally have 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
Ring A is a saturated, partially saturated or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
R1 is selected from the group consisting of
(a) a saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 additional heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, optionally attached through a C e alkylene chain, and optionally substituted by one or more R8;
(b)
(C)
(d)
Figure imgf000103_0002
Figure imgf000104_0001
Q is carbon, oxygen, or S(O)t; w is 1 or 2; each R2 is independently selected from the group consisting of -OR0, -C(O)-R°, -S(O)2-R°, -C(O)-N(R°)2, -S(O)2-N(R°)2, -(CH2)a-N(R°)(-Vb-R+), -(CH2)a-(-Vb-R+), halogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by one or more R6, cycloalkyl optionally substituted by one or more R8, and heterocyclyl optionally substituted by one or more R8; and two adjacent R2s on Ring A are optionally taken together to form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen; or two geminal R2s are optionally taken together to form a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, said fused or spiro ring being optionally substituted by one or more R8; each a independently is 0-3; each b independently is 0 or 1 ;
V is -C(O)-, -C(O)O-, -S(O)2-, or -C(O)-N(R0)-;
R+ is alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, or heterocyclyl, wherein said R+ is optionally substituted by one or more R8; d is 0-3 m is 0 or 1 ; n is 0-5;
R3 is H, -N(R°)2, -N(R°)C(O)R°, -CN, halogen, CF3, alkyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)1.6-N(R0)SO2(R0), alkenyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)1-6-N(R0)SO2(R0), alkynyl optionally substituted by one or more groups selected from R7 or -S-aryl optionally substituted by -(CH2)ι-6-N(R0)SO2(R0), cycloalkyl or carbocyclyl optionally substituted by one or more R8, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by one or more R6, or heterocyclyl optionally substituted by one or more R8;
Y is alkyl, alkenyl, alkynyl, -(CR4R5)P-, -C(O)-, -C(O)C(O)-, -C(S)-, -O-(CH2)o^-C(O)-, -(CH2)o.4-C(O)-O-, -N(R°)-C(O)-, -C(O)-N(R0)-, -N(R°)-C(S)-, -S(O)r, -O-C(=N-CN)-, -O-C(=N-R0)-, -C(=N-CN)-O-, -C(=N-CN)-S-, -C(=N-R°)-O-, -S-C(=N-CN)-, -N(R°)-C(=N-CN)-, -C(=N-CN)-, -N(R°)-C[=N-C(O)-R°], -N(R°)-C[=N-S(O)t-R°], -N(R°)-C(=N-OR0)-, -N(R°)-C(=N-R0)-, or -C(=N-R0)-; each R4 is independently H or alkyl optionally substituted by R7, alkenyl optionally substituted by R7, or alkynyl optionally substituted by R7; each R5 is independently selected from the group consisting of H, -C(O)-OR6, -C(O)-N(R°)2, -S(O)rN(R°)2, -S(O)ΓR0, aryl optionally substituted by R6, and heteroaryl optionally substituted by R6; p is 1-5; each t independently is 1 or 2; each R6 is independently selected from the group consisting of halogen, -CF3, -OCF3, -OR0, -(CH^-e-OR0, -SR°, -(CH2)ι-6-SR°, -SCF3, -R°, methylenedioxy, ethylenedioxy, -NO2, -CN, -(CH2).,.6-CN, -N(R°)2, -(CH2)ι-6-N(R°)2, -NR°C(O)R°, -NR°(CN), -NR0C(O)N(R°)2, -NR°C(S)N(R°)2, -NR°CO2R0, -NR°NR°C(O)R°, -NR°NR0C(O)N(R0)2, -NR0NR°CO2R°, -C(O)C(O)R°, -C(O)CH2C(O)R°, -(CH2)o.6CO2R0, -O-C(O)R°, -C(O)R°, -C(O)N(R°)N(R°)2, -C(O)N(R°)2, -C(O)N(R°)OH, -C(O)N(R°)SO2R°, -OC(O)N(R°)2, -S(O)tR°, -S(O)t-OR°, -S(O)tN(R°)C(O)R°, -S(O)tN(R°)OR°, -NR°SO2N(R0)2, -NR°SO2R°, -C(=S)N(R°)2, -C(=NH)-N(R°)2, -(CH2)1-6-C(O)R°, -C(=N-OR°)-N(R°)2, -O-(CH2)o-6-SO2N(R°)2, -(CH2)1.6NHC(O)R°, and -SO2N(R°)2 wherein the two R°s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur; each R7 is independently selected from the group consisting of halogen, -CF3, -R°, -OR0, -OCF3, -(CH2).,.6-OR0, -SR°, -SCF3, -(CH2)ι.6-SR°, aryl optionally substituted by R6, methylenedioxy, ethylenedioxy, -NO2, -CN, -(CH2)1.6-CN, -N(R°)2, -(CH2)1.6-N(R°)2, -NR°C(O)R°, -NR°(CN), -NR°C(O)N(R°)2, -N(R°)C(S)N(R°)2, -NR°CO2R0, -NR°NR°C(O)R°, -NR0NR°C(O)N(R°)2, -NR0NR°CO2R°, -C(O)C(O)R°, -C(O)CH2C(O)R°, -(CH2)o-6-CO2R°, -C(O)R°, -C(O)N(R°)N(R°)2, -C(O)N(R°)2, -C(O)N(R°)OH, -OC(O)R°, -C(O)N(R°)SO2R°, -OC(O)N(R°)2, -S(O)tR°, -S(O)t-OR°, -S(O)tN(R°)C(O)R°, -S(O)tN(R0)OR0, -NR°SO2N(R°)2, -NR°SO2R°, -C(=S)N(R°)2, -C(=NH)-N(R°)2, -(CH2)ι.6-C(O)R°, -C(=N-OR°)-N(R°)2, -O-(CH2)0-6-SO2N(R°)2, -(CH2)1.6-NHC(O)R°, and -SO2N(R°)2 wherein the two R°s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur; each R8 is independently selected from the group consisting of R7, =O, =S, =N(R°), and =N(CN); each R9 independently is hydrogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, cycloalkyl optionally substituted by one or more R8, heterocyclyl optionally substituted by one or more R8, heteroaryl optionally substituted by one or more R6, or aryl optionally substituted by one or more R6; or
-(Y)m-R3 and R9 may combined with the nitrogen atom with which they are attached to form a saturated, partially saturated, or aromatic 5-7 membered monocyclic or 8-10 membered bicyclic ring that optionally contains 1 to 3 additional heteroatoms selected oxygen, phosphorus, sulfur, or nitrogen, wherein said ring may be optionally substituted with one or more R8;
R10 is hydrogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynyl optionally substituted by one or more R7, cycloalkyl optionally substituted by one or more R8, heterocyclyl optionally substituted by one or more R8, heteroaryl optionally substituted by one or more R6, or aryl optionally substituted by one or more R6; each R° is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, and heterocyclylalkyl, wherein each member of R° except H is optionally substituted by one or more R*, OR*, N(R*)2, =O, =S, halogen, CF3, NO2, CN, -C(O)R*. -CO2R*, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-aralkyl, -S(O)t-aryl, -S(O)t-heteroaryl, -NR*SO2R*, -NR*C(O)R*, -NR*C(O)N(R*)2, -N(R*)C(S)N(R*)2, -NR*CO2R*, -NR*NR*C(O)R*, -NR*NR*C(O)N(R*)2, -NR*NR*CO2R*, -C(O)C(O)R*, -C(O)CH2C(O)R*, -C(O)N(R*)N(R*)2, -C(O)N(R*)2, -C(O)NR*SO2R*, -OC(O)N(R*)2> -S(O)tR*, -NR*SO2N(R*)2, -SO2N(R*)2 wherein the two R*s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen or sulfur; and each R* is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl.
2. A compound selected from the group consisting of
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Chiral
Figure imgf000110_0001
Figure imgf000110_0002
Chiral
Chiral
Figure imgf000110_0003
Chiral
Figure imgf000110_0004
Chiral
Figure imgf000111_0001
Chiral
chira|
Chiral
Figure imgf000111_0002
Chiral
Figure imgf000111_0003
Chiral
Figure imgf000112_0001
Figure imgf000112_0002
Chiral
Figure imgf000112_0003
Chiral
chiral
Figure imgf000112_0004
Chiral
Figure imgf000113_0001
Chiral
Figure imgf000113_0002
Figure imgf000113_0003
Chiral
Figure imgf000113_0004
Chiral
Chiral
Figure imgf000114_0001
hiral
Figure imgf000114_0002
Chiral
Figure imgf000115_0001
Figure imgf000115_0002
Chiral
Figure imgf000115_0003
Figure imgf000115_0004
Chiral
Figure imgf000115_0005
Chiral
Chiral
Figure imgf000116_0001
Chiral
Chiral
Figure imgf000116_0002
Figure imgf000116_0003
Figure imgf000117_0001
3. The compound of claim 1 wherein R10 is optionally substituted aryl.
4. The compound of claim 3 wherein R10 is optionally substituted phenyl.
5. The compound of claim 1 wherein R1 is
Figure imgf000118_0001
6. The compound of claim 5 wherein R9 is alkyl.
7. The compound of claim 6 wherein R9 is methyl.
8. The compound of claim 5 wherein -(Y)m-R is
Figure imgf000118_0002
The compound of claim 5 wherein -(Y)m-R3 is
Figure imgf000119_0001
ϊ r , °- , r^ , Ύo ; *0/>j ^o H, ?0 0
»
Figure imgf000119_0002
Figure imgf000120_0001
Figure imgf000121_0001
l IlI o -s II— S-CF, o °
Figure imgf000121_0002
Figure imgf000121_0003
,CN ,CN ,,CN ,CN N
N N I N I I ^s^0^
A- A-1- Aλ < ι 7^
Figure imgf000122_0001
0. The compound of claim 5 wherein -(Y)m-R3 and -R9 combine with the nitrogen atom to which they are attached to form
Figure imgf000123_0001
Figure imgf000123_0002
11. The compound of claim 1 wherein R1 is selected from the group consisting of
12. The compound of claim 1 wherein X is -(CH2)-, -(CH2-CH2)-, or -(CH2-CH2-CH2)-.
13. The compound of claim 12 wherein X is optionally substituted by one or more halogen or oxo.
14. The compound of claim 12 wherein X optionally has 1-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen.
15. The compound of claim 1 wherein the A ring is selected from:
Figure imgf000125_0001
Figure imgf000125_0002
Figure imgf000125_0003
16. The compound of claim 15 wherein each R2, with an asterisk indicating a point of substitution from Ring A, independently is selected from:
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
7. The compound of claim 1 wherein ring A, with two geminal R2s, is selected from:
Figure imgf000129_0001
18. The compound of claim 1 wherein the A ring is tropane or piperidine, either optionally substituted with one or more R2.
9. The compound of claim 18 wherein the A ring in combination with R2 is
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
20. The compound of claim 1 wherein the A ring contains at least one additional nitrogen atom and said A ring optionally is N-substituted.
21. The compound of claim 20 wherein the A ring is N-substituted with -(CH2)a-(Vb-R+).
22. A method of treatment of a viral infection in a mammal comprising administering to said mammal an antiviral effective amount of a compound according to claims 1-21.
23. A method according to claim 22 wherein the viral infection is an HIV infection.
24. A method of treatment of a bacterial infection in a mammal comprising administering to said mammal an effective amount of a compound according to claims 1-21.
25. A method according to claim 24 wherein the bacterium is Yersinia pestis.
26. A method of treatment of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders in a mammal comprising administering to said mammal a pharmceutically effective amount of a compound according to claims 1-21.
27. A compound according to claims 1-21 for use in medical therapy.
28. Use of a compound according to claims 1-21 in the manufacture of a medicament for the treatment of a viral infection.
29. The use according to claim 28 wherein the viral infection is a HIV infection.
30. Use of a compound according to claims 1-21 in the manufacture of a medicament for the treatment of a bacterial infection.
31. The use according to claim 30 wherein the bacterium is Yersinia pestis.
32. Use of a compound according to claims 1-21 in the manufacture of a medicament for the treatment of multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease , autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, infectious disorders including bubonic and pneumonic plague, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis and immune mediated disorders.
33. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claims 1-21 together with a pharmaceutically acceptable carrier.
34. The pharmaceutical composition according to claim 33 in the form of a tablet or capsule.
35. The pharmaceutical composition according to claim 33 in the form of a liquid.
36. A method of treatment of a viral infection in a mammal comprising administering to said mammal a composition comprising a compound according to claims 1-21 and another therapeutic agent.
37. The method according to claim 36, wherein said composition comprises another therapeutic agent selected from the group consisting of (1 -alpha, 2-beta, 3- alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir, acyclic nucleoside phosphonates, (S)-1-(3-hydroxy-2- phosphonyl-methoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9- yl)ethoxy]methyl]phosphinylidene] bis(oxymethylene)-2,2-dimethylpropanoic acid (bis-POM PMEA, adefovir dipivoxil), [[(1R)-2-(6-amino-9H-purin-9-yl)-1- methylethoxy]methyl]phosphonic acid (tenofovir), (R)-[[2-(6-Amino-9H-purin-9-yl)- 1 -methylethoxyjmethyljphosphonic acid bis-(isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA), ribonucleotide reductase inhibitors, 2-acetylpyridine 5-[(2- chloroanilino)thiocarbonyl) thiocarbonohydrazone and hydroxyurea, nucleoside reverse transcriptase inhibitors, 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'-dideoxyadenosine, 2',3'- dideoxyinosine (ddl, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)- beta-D-2,6-diaminopurine dioxolane (DAPD), 3'-azido-2',3'-dideoxythymidine-5'- H-phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), (-)-cis- 1-(2-hydroxymethyl)-1 ,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2- (hydroxymethyl)-l ,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'- fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol (abacavir), 9-[4- hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G) ribavirin, protease inhibitors, indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, fosamprenavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5- yloxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5- dimethyl- 1 ,3-thiazolidine-4-carboxamide (KNI-272), 4R-(4alpha,5alpha,6beta)]-1 ,3-bis[(3- aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1 ,3- diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5- trifluoromethylpyridinyl)-sulfonylamino]phenyl]propyl]-4- hydroxy-6alpha- phenethyl-6beta-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy- 3(S)-[N-(methoxycarbonyl)-l-tert-leucylamino]-4- phenylbutyl-N alpha- (methoxycarbonyl)-N,-[4-(2-pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5- dimethyl-N-(2-methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)- hydroxy-1(S)-indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(1-(4- benzo[b]furanylmethyl)-2(S)-N'-(tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A), interferons, α-interferon, renal excretion inhibitors, probenecid, nucleoside transport inhibitors, dipyridamole, pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin, phosphonoformic acid, immunomodulators, interleukin II, thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD and genetically engineered derivatives thereof, non- nucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (BI-RG-587), alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-benzeneacetamide (loviride), 1 -[3-(isopropylamino)-2-pyridyl]-4-[5-(methanesulfonamido)-1 H-indol-2- ylcarbonyljpiperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12- hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11,12-dihydro-2H, 6H, 10H-benzo(1, 2- b:3, 4-b':5, 6-b")tripyran-2-one ((+) calanolide A), (4S)-6-Chloro-4-[1 E)- cyclopropylethenyl)-3,4- dihydro-4-(trifluoromethyl)-2(1 H)-quinazolinone (DPC- 083), (S)-6-chloro-4-(cyclopropylethynyl)-1 ,4-dihydro-4-(trifluoromethyl)-2H-3, 1 - benzoxazin-2-one (efavirenz, DMP 266), 1-(ethoxymethyl)-5-(1~methylethyl)-6- (phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-442), and 5-(3,5- dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1H-imidazol-2-ylmethyl carbamate (capravirine), glycoprotein 120 antagonists, PRO-2000, PRO-542, 1,4- bis[3-[(2, 4- dichlorophenyl)carbonylamino]-2-oxo-5,8- disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1 , 4-dihydrazone (FP-21399), cytokine antagonists, reticulose (Product-R), 1,1'-azobis-formamide (ADA), 1,11- (1 ,4-phenylenebis(methylene))bis-1 ,4,8,11 -tetraazacyclotetradecane octahydrochloride (AMD-3100), integrase inhibitors, and fusion inhibitors.
38. A method of treatment of a viral infection in a mammal comprising administering to said mammal a composition comprising a compound according to claims 1-21 and ritonavir.
PCT/US2003/039619 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists Ceased WO2004055010A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60318891T DE60318891T2 (en) 2002-12-13 2003-12-12 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
AU2003296993A AU2003296993A1 (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists
JP2004560831A JP2006514950A (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as CCR5 antagonists
EP03813416A EP1569934B1 (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists
US10/538,196 US7569579B2 (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43362602P 2002-12-13 2002-12-13
US60/433,626 2002-12-13

Publications (2)

Publication Number Publication Date
WO2004055010A2 true WO2004055010A2 (en) 2004-07-01
WO2004055010A3 WO2004055010A3 (en) 2004-12-23

Family

ID=32595221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039619 Ceased WO2004055010A2 (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists

Country Status (8)

Country Link
US (1) US7569579B2 (en)
EP (1) EP1569934B1 (en)
JP (1) JP2006514950A (en)
AT (1) ATE384724T1 (en)
AU (1) AU2003296993A1 (en)
DE (1) DE60318891T2 (en)
ES (1) ES2298627T3 (en)
WO (1) WO2004055010A2 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007614A1 (en) * 2003-07-03 2005-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 Monoamine oxidase inhibitors
WO2005058884A3 (en) * 2003-12-15 2005-09-09 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011098452A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
US8063215B2 (en) 2007-08-22 2011-11-22 Astrazeneca Ab Cyclopropyl amide derivatives
CN102947265A (en) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 Lysine specific demethylase-1 inhibitors and their use
WO2013090664A1 (en) 2011-12-16 2013-06-20 Glaxosmithkline Llc Derivatives of betulin
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9012452B2 (en) 2010-02-18 2015-04-21 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
EP3000813A1 (en) 2008-08-11 2016-03-30 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2016075661A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US9790196B2 (en) 2010-11-30 2017-10-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae
EP3246030A1 (en) 2008-08-11 2017-11-22 GlaxoSmithKline LLC Novel adenine derivatives
US9908859B2 (en) 2011-02-08 2018-03-06 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1161240B1 (en) * 1998-12-18 2005-08-17 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (en) 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
DE60216753T2 (en) * 2001-02-16 2008-01-03 Aventis Pharmaceuticals Inc. HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DORN C P ET AL: "Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes " BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 2, January 2001 (2001-01), pages 259-264, XP004314862 ISSN: 0960-894X *
FINKE P E ET AL: "Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)ami no]-4-(piperidin-1-yl)butanes" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 2, January 2001 (2001-01), pages 265-270, XP004314863 ISSN: 0960-894X *
FINKE PAUL E ET AL: "Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-(N-(methyl)-N-(phenylsulfonyl)amin o)-2-(phenyl)-4-(4-(substituted)piperidin- 1-yl)butanes" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 18, 2001, pages 2469-2473, XP002962948 ISSN: 0960-894X *
KUMAR S ET AL: "PHARMACOKINETICS AND INTERACTIONS OF A NOVEL ANTAGONIST OF CHEMOKINE RECEPTOR 5 (CCR5) WITH RITONAVIR IN RATS AND MONKEYS: ROLE OF CYP3A AND P-GLYCOPROTEIN" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 304, no. 3, 1 March 2003 (2003-03-01), pages 1161-1171, XP009019167 ISSN: 0022-3565 *
MAEDA K ET AL: "The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection" CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS,, NL, vol. 4, no. 5, October 2004 (2004-10), pages 447-452, XP004558853 ISSN: 1471-4892 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007614A1 (en) * 2003-07-03 2005-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 Monoamine oxidase inhibitors
WO2005058884A3 (en) * 2003-12-15 2005-09-09 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof
US7351825B2 (en) 2003-12-15 2008-04-01 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
US8063215B2 (en) 2007-08-22 2011-11-22 Astrazeneca Ab Cyclopropyl amide derivatives
US9029381B2 (en) 2007-08-22 2015-05-12 Astrazeneca Ab Cyclopropyl amide derivatives
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EP3000813A1 (en) 2008-08-11 2016-03-30 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EP3246030A1 (en) 2008-08-11 2017-11-22 GlaxoSmithKline LLC Novel adenine derivatives
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011098452A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
US9012452B2 (en) 2010-02-18 2015-04-21 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
US8722743B2 (en) 2010-04-19 2014-05-13 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
CN102947265A (en) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 Lysine specific demethylase-1 inhibitors and their use
CN102947265B (en) * 2010-04-19 2015-07-29 奥瑞泽恩基因组学股份有限公司 Methionin specific demethylase-1 inhibitor and application thereof
US10202330B2 (en) 2010-04-19 2019-02-12 Oryzon Genomics, Sa Lysine specific demethylase-1 inhibitors and their use
US9149447B2 (en) 2010-04-19 2015-10-06 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
US9676701B2 (en) 2010-07-29 2017-06-13 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US10233178B2 (en) 2010-07-29 2019-03-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
US9708309B2 (en) 2010-07-29 2017-07-18 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
US9790196B2 (en) 2010-11-30 2017-10-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae
US9908859B2 (en) 2011-02-08 2018-03-06 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US10329256B2 (en) 2011-10-20 2019-06-25 Oryzon Genomics, S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9670136B2 (en) 2011-10-20 2017-06-06 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US10214477B2 (en) 2011-10-20 2019-02-26 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9944601B2 (en) 2011-10-20 2018-04-17 Oryzon Genomics, S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
WO2013090664A1 (en) 2011-12-16 2013-06-20 Glaxosmithkline Llc Derivatives of betulin
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
WO2016075661A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP4032885A1 (en) 2016-04-07 2022-07-27 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
US11613525B2 (en) 2018-05-16 2023-03-28 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds

Also Published As

Publication number Publication date
AU2003296993A1 (en) 2004-07-09
US20060052408A1 (en) 2006-03-09
AU2003296993A8 (en) 2004-07-09
DE60318891D1 (en) 2008-03-13
ES2298627T3 (en) 2008-05-16
EP1569934B1 (en) 2008-01-23
WO2004055010A3 (en) 2004-12-23
ATE384724T1 (en) 2008-02-15
EP1569934A2 (en) 2005-09-07
DE60318891T2 (en) 2009-01-22
US7569579B2 (en) 2009-08-04
JP2006514950A (en) 2006-05-18

Similar Documents

Publication Publication Date Title
US7569579B2 (en) Cyclopropyl compounds as ccr5 antagonists
US7271172B2 (en) Pyrrolidine and azetidine compounds as CCR5 antagonists
US7589207B2 (en) Cyclohexyl compounds as CCR5 antagonists
US7589204B2 (en) Indane compounds as CCR5 antagonists
US7645771B2 (en) CCR5 antagonists as therapeutic agents
US20090053172A1 (en) Heterocyclic compounds as ccr5 antagonists
EP1720856B1 (en) Hiv integrase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006052408

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10538196

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003813416

Country of ref document: EP

Ref document number: 2004560831

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003813416

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10538196

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003813416

Country of ref document: EP